[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 169
1. Mnif I, Chaker M, Daoud E, Ben Mahfoudh K, Mnif Z, Mnif J: [Central neurocytoma: three case reports]. J Neuroradiol; 2008 Mar;35(1):56-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Neurocytome central: à propos de trois observations.
  • Central neurocytoma is classically recognized as an intraventricular benign brain tumour.
  • Histologically, central neurocytoma presents remarkable likeness characteristics to oligodendroglioma, but immunohistochemical study distinguishes this tumour.
  • Imaging appearances (CT, MRI) raise the diagnosis and immunohistochemical study confirm it.
  • The purpose of our work is to assess the value of imaging (CT, MRI) in the diagnosis of central neurocytoma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Neurocytoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17617462.001).
  • [ISSN] 0150-9861
  • [Journal-full-title] Journal of neuroradiology. Journal de neuroradiologie
  • [ISO-abbreviation] J Neuroradiol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


2. Schoene-Bake JC, Parpaley Y, Weber B, Panksepp J, Hurwitz TA, Coenen VA: Tractographic analysis of historical lesion surgery for depression. Neuropsychopharmacology; 2010 Dec;35(13):2553-63
MedlinePlus Health Information. consumer health - Depression.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Various surgical brain ablation procedures for the treatment of refractory depression were developed in the twentieth century.
  • It is possible that the observed clinical improvements of these various surgical procedures may reflect shared influences on presently unspecified brain affect-regulating networks.
  • Such possibilities can now be analyzed using modern brain connectivity procedures such as diffusion tensor imaging (DTI) tractography.
  • Accordingly, modestly sized historical lesions, especially of the anatomical overlap areas, were 'implanted' in brain-MRI scans of 53 healthy subjects.
  • [MeSH-major] Brain / anatomy & histology. Depression / surgery. Neural Pathways / anatomy & histology. Neuroanatomical Tract-Tracing Techniques / methods. Psychosurgery / methods

  • Genetic Alliance. consumer health - Depression.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Image Anal. 2001 Jun;5(2):143-56 [11516708.001]
  • [Cites] Neurosurg Focus. 2008;25(1):E2 [18590379.001]
  • [Cites] Neurosurgery. 2002 May;50(5):1043-9; discussion 1049-52 [11950407.001]
  • [Cites] Neurol Med Chir (Tokyo). 2002 Sep;42(9):365-71 [12371591.001]
  • [Cites] JAMA. 2003 Jun 18;289(23):3095-105 [12813115.001]
  • [Cites] Nat Neurosci. 2003 Jul;6(7):750-7 [12808459.001]
  • [Cites] Neurosurg Clin N Am. 2003 Apr;14(2):199-212 [12856488.001]
  • [Cites] Neurosurg Clin N Am. 2003 Apr;14(2):225-35 [12856490.001]
  • [Cites] Stereotact Funct Neurosurg. 2002;79(3-4):234-44 [12890982.001]
  • [Cites] Br J Psychiatry. 1969 Mar;115(520):257-66 [4893673.001]
  • [Cites] Exp Neurol. 1973 Sep;40(3):798-805 [4124980.001]
  • [Cites] Br J Psychiatry. 1973 Aug;123(573):141-8 [4582235.001]
  • [Cites] Med J Aust. 1973 Aug 25;2(8):366-71 [4749527.001]
  • [Cites] Postgrad Med J. 1973 Dec;49(578):860-4 [4618905.001]
  • [Cites] Br J Psychiatry. 1976 Mar;128:226-40 [1252686.001]
  • [Cites] Stereotact Funct Neurosurg. 1991;57(4):175-94 [1842976.001]
  • [Cites] J Clin Psychiatry. 1993 Nov;54(11):405-18 [8270583.001]
  • [Cites] Br J Psychiatry. 1994 Nov;165(5):599-611; discussion 612-3 [7866675.001]
  • [Cites] Annu Rev Psychol. 1995;46:209-35 [7872730.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1995 Winter;7(1):103-12 [7711480.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1995 Spring;7(2):230-4 [7626968.001]
  • [Cites] Arch Gen Psychiatry. 1961 Jun;4:561-71 [13688369.001]
  • [Cites] Cereb Cortex. 2005 Jan;15(1):31-9 [15238447.001]
  • [Cites] Neuron. 2005 Mar 3;45(5):651-60 [15748841.001]
  • [Cites] Gesnerus. 2005;62(1-2):77-101 [16201322.001]
  • [Cites] Neuroimage. 2006 May 15;31(1):440-57 [16466680.001]
  • [Cites] Stereotact Funct Neurosurg. 2006;84(5-6):228-35 [17063044.001]
  • [Cites] Neuroimage. 2007 Jan 1;34(1):144-55 [17070705.001]
  • [Cites] Brain. 2007 Mar;130(Pt 3):630-53 [17293361.001]
  • [Cites] Neuroimage. 2007 May 1;35(4):1531-7 [17391987.001]
  • [Cites] Ann N Y Acad Sci. 2007 May;1104:70-88 [17344522.001]
  • [Cites] Brain Res Rev. 2007 Dec;56(2):283-321 [17905440.001]
  • [Cites] Neuropsychopharmacology. 2008 Jan;33(2):368-77 [17429407.001]
  • [Cites] J Clin Neurosci. 2008 Feb;15(2):138-42 [18068369.001]
  • [Cites] CNS Spectr. 2008 Aug;13(8):663-81 [18704022.001]
  • [Cites] Biol Psychiatry. 2008 Sep 15;64(6):461-7 [18639234.001]
  • [Cites] Psychiatry Res. 2008 Nov 30;164(2):132-42 [18945599.001]
  • [Cites] Nat Neurosci. 2009 Jan;12(1):32-4 [19029888.001]
  • [Cites] Biol Psychiatry. 2009 Feb 15;65(4):276-82 [19013554.001]
  • [Cites] J Clin Invest. 2009 Apr;119(4):717-25 [19339763.001]
  • [Cites] Science. 2009 Apr 17;324(5925):354-9 [19299587.001]
  • [Cites] Neurosurgery. 2009 Jun;64(6):1106-14; discussion 1114-5 [19487890.001]
  • [Cites] J Neurosurg. 2009 Dec;111(6):1209-15 [19480538.001]
  • [Cites] Biol Psychiatry. 2010 Jan 15;67(2):117-24 [19819426.001]
  • [Cites] Neuropsychopharmacology. 2010 Jan;35(1):4-26 [19812543.001]
  • [Cites] CNS Drugs. 2010 Feb;24(2):131-61 [20088620.001]
  • [Cites] Neuron. 2010 Mar 25;65(6):748-51 [20346752.001]
  • [Cites] J Psychiatr Res. 2010 Aug;44(11):683-7 [20096858.001]
  • [Cites] Neuroimage. 2008 Apr 1;40(2):570-82 [18255316.001]
  • [Cites] Biol Psychiatry. 2008 Apr 1;63(7):670-7 [17916331.001]
  • [Cites] Cereb Cortex. 2008 Jun;18(6):1374-83 [17928332.001]
  • [Cites] J Nerv Ment Dis. 2008 May;196(5):405-10 [18477883.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Aug 29;356(1412):1293-322 [11545704.001]
  • (PMID = 20736994.001).
  • [ISSN] 1740-634X
  • [Journal-full-title] Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
  • [ISO-abbreviation] Neuropsychopharmacology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3055575
  •  go-up   go-down


3. McCarthy BJ, Kruchko C, Central Brain Tumor Registry of the United States: Consensus conference on cancer registration of brain and central nervous system tumors. Neuro Oncol; 2005 Apr;7(2):196-201
Genetic Alliance. consumer health - Brain Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consensus conference on cancer registration of brain and central nervous system tumors.
  • The passage of Public Law 107-260, the Benign Brain Tumor Cancer Registries Amendment Act, in October 2002 has made the collection of all primary brain tumors a reality.
  • However, at the first Consensus Conference on Brain Tumor Definition for Registration in 2002, and during the development of training materials for benign brain tumor collection, several issues were identified that were tabled for future discussion.
  • These and other issues were addressed at the subsequent 2003 Consensus Conference on Cancer Registration of Brain and Central Nervous System Tumors, at which the Central Brain Tumor Registry of the United States facilitated a discussion among epidemiologists, neurosurgeons, and neuropathologists.
  • (1) amend the histology coding scheme for cysts and tumor-like lesions that currently have a code in the third edition of the International Classification of Disease for Oncology (ICDO), (2) collect data on all instances of specific cysts and tumor-like lesions that are located in brain and other CNS sites but currently lack ICDO codes, (3) establish a new ICDO topography site for skull base tumors for the brain and CNS, and (4) collect data on genetic syndromes in patients diagnosed with brain or CNS tumors.
  • Because classification of primary intracranial and other CNS tumors is dynamic, and the registration and coding of these tumors will need to be periodically reviewed.
  • [MeSH-major] Central Nervous System Neoplasms / classification. Central Nervous System Neoplasms / pathology. Registries

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1998 Jul 15;90(14):1039-71 [9672254.001]
  • [Cites] Neuro Oncol. 2002 Apr;4(2):134-45 [11916506.001]
  • (PMID = 15831238.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  • [Other-IDs] NLM/ PMC1871892
  •  go-up   go-down


Advertisement
4. Pattanayak Mohanty S, Ray JG, Richa, Mukherjee S, Mandal C, Chaudhuri K: Melanotic neuroectodermal tumour of infancy. BMJ Case Rep; 2010;2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanotic neuroectodermal tumour of infancy.
  • Melanotic neuroectodermal tumour of infancy (MNTI) is a rare benign tumour of neural crest origin that was first described by Krompecher in 1918.1 It is predominantly found in infancy, with about 92% of cases below the age of 12 months and 82% below the age of 6 months.
  • The predominant site of origin is in the premaxilla though it is reported at other sites also including the skull, the mandible, the epididymis and the brain.2 The lesions often have areas of bluish discolouration on the surface and are characterised by displacement of the involved tooth bud and local aggressiveness.
  • The clinical, radiological, histological and immunohistochemical findings, confirmed the diagnosis of MNTI.
  • [MeSH-major] Maxillary Neoplasms / diagnosis. Neuroectodermal Tumor, Melanotic / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Infant. Male. Maxilla / pathology. Maxilla / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Oral Maxillofac Surg. 1995 Dec;33(6):375-80 [8838953.001]
  • [Cites] Am J Surg Pathol. 1993 Jun;17(6):566-73 [8392815.001]
  • [Cites] J Pathol Bacteriol. 1964 Jan;87:179-81 [14106343.001]
  • [Cites] Cancer. 1965 Mar;18:381-7 [14264038.001]
  • [Cites] Cancer. 1965 Apr;18:477-84 [14278044.001]
  • [Cites] Br J Surg. 1960 Mar;47:574-6 [14401129.001]
  • [Cites] Surgery. 1947 Nov;22(5):837-41 [18897075.001]
  • [Cites] Med Pediatr Oncol. 2003 Mar;40(3):198-9 [12518354.001]
  • [Cites] Cancer. 1966 Feb;19(2):196-206 [4285905.001]
  • [Cites] J Oral Surg. 1975 Nov;33(11):858-65 [171357.001]
  • [Cites] J Oral Pathol. 1977 Jul;6(4):221-32 [196061.001]
  • [Cites] Cancer. 1979 Apr;43(4):1389-410 [221089.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1980 Apr;49(4):279-85 [6244526.001]
  • [Cites] Cancer. 1981 Jul 15;48(2):257-70 [6263455.001]
  • [Cites] Int J Oral Surg. 1981 Dec;10(6):432-46 [6286519.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1987 Jan-Feb;96(1 Pt 1):128-9 [3028235.001]
  • [Cites] J Craniomaxillofac Surg. 1988 Oct;16(7):330-6 [2848872.001]
  • [Cites] Am J Surg Pathol. 1991 Mar;15(3):233-45 [1847607.001]
  • [Cites] J Oral Maxillofac Surg. 1992 Aug;50(8):886-94 [1321897.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1956 Nov;9(11):1197-209 [13370112.001]
  • (PMID = 22797196.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029448
  •  go-up   go-down


5. McDonald A: Living with a benign brain tumour. BMJ; 2009;339:b2886
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Living with a benign brain tumour.
  • [MeSH-major] Brain Neoplasms / psychology. Glioma, Subependymal / psychology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19638372.001).
  • [ISSN] 1756-1833
  • [Journal-full-title] BMJ (Clinical research ed.)
  • [ISO-abbreviation] BMJ
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Minniti G, Amichetti M, Enrici RM: Radiotherapy and radiosurgery for benign skull base meningiomas. Radiat Oncol; 2009;4:42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy and radiosurgery for benign skull base meningiomas.
  • Complex combined surgical approaches are more likely to achieve complete tumor removal, but frequently at a cost of treatment related high morbidity.
  • Local control following subtotal excision of benign meningiomas can be improved with conventional fractionated external beam radiation therapy with a reported 5-year progression-free survival up to 95%.
  • New radiation techniques, including stereotactic radiosurgery (SRS), fractionated stereotactic radiotherapy (FSRT), and intensity-modulated radiotherapy (IMRT) have been developed as a more accurate technique of irradiation with more precise tumor localization, and consequently a reduction in the volume of normal brain irradiated to high radiation doses.
  • SRS achieves a high tumour control rate in the range of 85-97% at 5 years, although it should be recommended only for tumors less than 3 cm away more than 3 mm from the optic pathway because of high risk of long-term neurological deficits.
  • The reported results indicate a high tumour control rate in the range of 85-100% at 5 years with a low risk of significant incidence of long-term toxicity.
  • Because of the long natural history of benign meningiomas, larger series and longer follow-up are necessary to compare results and toxicity of different techniques.
  • [MeSH-major] Meningioma / radiotherapy. Meningioma / surgery. Skull Base Neoplasms / radiotherapy. Skull Base Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1412-22 [16029801.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1427-31 [16029803.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2005 Oct;76(10):1425-30 [16170090.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):491-7 [16235682.001]
  • [Cites] Neurosurgery. 2005 Nov;57(5):873-86; discussion 873-86 [16284558.001]
  • [Cites] Technol Cancer Res Treat. 2005 Dec;4(6):675-82 [16292888.001]
  • [Cites] Surg Neurol. 2006 Jan;65(1):28-33; discussion 33-4 [16378847.001]
  • [Cites] Neurosurgery. 2006 Jan;58(1):28-36; discussion 28-36 [16385326.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 May;64(5):542-8 [16649974.001]
  • [Cites] Radiat Oncol. 2006;1:46 [17173702.001]
  • [Cites] Radiother Oncol. 2007 Jan;82(1):90-5 [17161483.001]
  • [Cites] Neurosurgery. 2006 Dec;59(6):1188-94; discussion 1194 [17277681.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):858-63 [17379447.001]
  • [Cites] J Neurosurg. 2007 Aug;107(2):325-36 [17695387.001]
  • [Cites] Neurosurgery. 2007 Aug;61(2):281-6; discussion 286-7 [17762740.001]
  • [Cites] J Neurosurg. 2007 Oct;107(4):745-51 [17937218.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:68-73 [11143266.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):99-105 [11163502.001]
  • [Cites] Neurosurgery. 2001 Feb;48(2):285-94; discussion 294-6 [11220370.001]
  • [Cites] J Neurosurg. 2001 May;94(5):816-21 [11354416.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3547-53 [11481362.001]
  • [Cites] Surg Neurol. 2001 Jun;55(6):325-31 [11483185.001]
  • [Cites] J Neurosurg. 2001 Sep;95(3):435-9 [11565865.001]
  • [Cites] Radiother Oncol. 2001 Oct;61(1):65-70 [11578730.001]
  • [Cites] J Neurosurg. 2001 Oct;95(4):710-3 [11596968.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):880-914 [11704310.001]
  • [Cites] Acta Neurochir (Wien). 2001 Nov;143(11):1141-52 [11731865.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E6 [17961043.001]
  • [Cites] J Neurosurg. 2007 Nov;107(5):937-44 [17977264.001]
  • [Cites] Neurosurgery. 2008 Jan;62(1):53-8; discussion 58-60 [18300891.001]
  • [Cites] Zentralbl Neurochir. 2008 Feb;69(1):14-21 [18393160.001]
  • [Cites] Prog Neurol Surg. 2009;22:96-111 [18948722.001]
  • [Cites] Can J Neurol Sci. 2002 Aug;29(3):240-8 [12195613.001]
  • [Cites] Acta Neurochir Suppl. 2002;84:71-6 [12379007.001]
  • [Cites] Neurosurgery. 2002 Dec;51(6):1373-79; discussion 1379-80 [12445342.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):362-72 [12527049.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1177-81 [12654424.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1436-40; discussion 1440-2 [12762888.001]
  • [Cites] Surg Neurol. 2003 Jul;60(1):60-7; discussion 67 [12865017.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1473-82 [14508835.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):101-11 [15093905.001]
  • [Cites] Neurosurgery. 2004 Jun;54(6):1375-83; discussion 1383-4 [15157294.001]
  • [Cites] Radiother Oncol. 2004 Jun;71(3):251-8 [15172139.001]
  • [Cites] Neurosurgery. 1982 Mar;10(3):332-9 [7070635.001]
  • [Cites] J Neurosurg. 1984 Mar;60(3):500-5 [6607981.001]
  • [Cites] J Clin Oncol. 1984 Oct;2(10):1139-43 [6491698.001]
  • [Cites] Neurosurgery. 1987 Apr;20(4):525-8 [3587542.001]
  • [Cites] Neurosurgery. 1989 Jan;24(1):12-7 [2927589.001]
  • [Cites] Neurosurgery. 1992 Jul;31(1):2-12 [1641106.001]
  • [Cites] J Neurooncol. 1992 Jun;13(2):157-64 [1432033.001]
  • [Cites] Acta Neurochir (Wien). 1993;122(1-2):60-70 [8333310.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):627-42 [8120563.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):245-51 [8027808.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):755-63 [7960976.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):315-21 [7673018.001]
  • [Cites] Neurosurgery. 1995 Jul;37(1):1-9; discussion 9-10 [8587667.001]
  • [Cites] Neurosurgery. 1996 Nov;39(5):915-9; discussion 919-20 [8905745.001]
  • [Cites] Ophthalmology. 1996 Nov;103(11):1761-6; discussion 1766-7 [8942867.001]
  • [Cites] J Neurosurg. 2008 Nov;109(5):804-10 [18976068.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1324-32 [18922647.001]
  • [Cites] Neurosurgery. 2009 Feb;64(2 Suppl):A7-13 [19165077.001]
  • [Cites] Acta Neurochir (Wien). 2009 Jan;151(1):1-8 [19093071.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(6):647-52; discussion 652-3 [10949439.001]
  • [Cites] Lancet. 2000 Nov 4;356(9241):1576-7 [11075777.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1363-70 [11121635.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1371-80 [11121636.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2002 Apr;14(2):103-9 [12069116.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):992-1000 [12095568.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1265-70 [12128128.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):65-72 [12134934.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):238-44; discussion 245-7 [9007855.001]
  • [Cites] Stereotact Funct Neurosurg. 1996;66 Suppl 1:121-8 [9032852.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):427-36 [9308947.001]
  • [Cites] Acta Neurol Scand. 1997 Nov;96(5):297-304 [9404999.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):43-50 [9420071.001]
  • [Cites] Stereotact Funct Neurosurg. 1998 Oct;70 Suppl 1:19-32 [9782232.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):321-7 [10030256.001]
  • [Cites] Stereotact Funct Neurosurg. 1998;71(1):43-50 [10072673.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):75-9 [10219797.001]
  • [Cites] J Neurosurg. 1999 May;90(5):823-7 [10223446.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(5):473-80 [10392202.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):42-9 [10413154.001]
  • [Cites] Cancer Radiother. 1999 Jul-Aug;3(4):311-7 [10486542.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Nov;61(5):531-43 [15521954.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1515-9 [15590183.001]
  • [Cites] Neurosurg Focus. 2003 May 15;14(5):e5 [15669816.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Dec;47(6):333-8 [15674748.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):800-4 [15562021.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):809-16 [15708260.001]
  • (PMID = 19828022.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 93
  • [Other-IDs] NLM/ PMC2768735
  •  go-up   go-down


7. Xu Q, Yuan X, Tunici P, Liu G, Fan X, Xu M, Hu J, Hwang JY, Farkas DL, Black KL, Yu JS: Isolation of tumour stem-like cells from benign tumours. Br J Cancer; 2009 Jul 21;101(2):303-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolation of tumour stem-like cells from benign tumours.
  • We set out to test whether tumour stem-like cells can be identified from benign tumours.
  • METHODS: Tumour sphere cultures were derived from hormone-positive and -negative pituitary adenomas.
  • Characterisation of tumour stem-like cells in vitro was performed using self-renewal assays, stem cell-associated marker expression analysis, differentiation, and stimulated hormone production assays.
  • The tumour-initiating capability of these tumour stem-like cells was tested in serial brain tumour transplantation experiments using SCID mice.
  • RESULTS: In this study, we isolated sphere-forming, self-renewable, and multipotent stem-like cells from pituitary adenomas, which are benign tumours.
  • Finally, we demonstrated that PASCs are pituitary tumour-initiating cells in serial transplantation animal experiments.
  • CONCLUSION: This study for the first time indicates that stem-like cells are present in benign tumours.
  • The conclusions from this study may have applications to understanding pituitary tumour biology and therapies, as well as implications for the notion of tumour-initiating cells in general.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] Nature. 2003 May 15;423(6937):255-60 [12714970.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Sep;75 Suppl 3:iii47-52 [15316045.001]
  • [Cites] Curr Opin Genet Dev. 2004 Oct;14(5):567-74 [15380249.001]
  • [Cites] Mol Endocrinol. 1994 Jul;8(7):878-85 [7527122.001]
  • [Cites] Annu Rev Med. 1996;47:95-106 [8712806.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9392-400 [15558011.001]
  • [Cites] J Endocrinol. 2005 Jan;184(1):41-50 [15642781.001]
  • [Cites] Mol Endocrinol. 2005 Apr;19(4):964-71 [15637144.001]
  • [Cites] Endocrinology. 2005 May;146(5):2376-87 [15677762.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • [Cites] J Neurosci Res. 2005 May 15;80(4):456-66 [15795928.001]
  • [Cites] Exp Cell Res. 2005 Aug 1;308(1):166-76 [15916758.001]
  • [Cites] J Clin Pharmacol. 2005 Aug;45(8):872-7 [16027397.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):650-3 [18385740.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R10 [18241344.001]
  • [Cites] Breast Cancer Res. 2008;10(2):105 [18423071.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] Neuroscience. 2008 Jun 23;154(2):541-50 [18462887.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):593-8 [19052619.001]
  • [Cites] Stem Cells. 2008 Dec;26(12):3018-26 [18787206.001]
  • [Cites] Endocrinology. 2005 Sep;146(9):3985-98 [15932930.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Glia. 2006 Feb;53(3):294-303 [16265670.001]
  • [Cites] Clin Adv Hematol Oncol. 2006 Jan;4(1):63-72 [16562373.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Genes Dev. 2006 Oct 1;20(19):2739-53 [17015435.001]
  • [Cites] Stem Cells. 2006 Nov;24(11):2382-90 [16857898.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Neuroendocrinology. 2007;85(2):110-30 [17337880.001]
  • [Cites] Physiol Rev. 2007 Jul;87(3):933-63 [17615393.001]
  • [Cites] Science. 2007 Jul 20;317(5836):337 [17641192.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1109-23 [18083101.001]
  • [Cites] Dev Neurosci. 2000;22(1-2):139-53 [10657706.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1180-7 [10720059.001]
  • [Cites] Mod Pathol. 2001 Sep;14(9):892-9 [11557786.001]
  • [Cites] Clin Neurosurg. 2001;48:306-19 [11692649.001]
  • [Cites] Science. 2002 Mar 22;295(5563):2231-5 [11910101.001]
  • [Cites] Ultrastruct Pathol. 2002 Jul-Aug;26(4):219-28 [12227947.001]
  • [Cites] Exp Neurol. 2002 Dec;178(2):288-93 [12504887.001]
  • [Cites] Pituitary. 2002;5(2):89-98 [12675506.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):285-95 [15057288.001]
  • (PMID = 19568241.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS048959-04; United States / NINDS NIH HHS / NS / R01 NS048959; United States / NINDS NIH HHS / NS / NS048959; United States / NINDS NIH HHS / NS / R01 NS048959-04; United States / NINDS NIH HHS / NS / R56 NS048959; United States / NINDS NIH HHS / NS / R21 NS048879-02; United States / NINDS NIH HHS / NS / NS048879-02; United States / NINDS NIH HHS / NS / R21 NS048879; United States / NINDS NIH HHS / NS / NS048879
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hypothalamic Hormones; 0 / Pituitary Hormones
  • [Other-IDs] NLM/ PMC2720199
  •  go-up   go-down


8. Guan M, Chen Y: Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score. J Clin Pathol; 2005 Nov;58(11):1175-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score.
  • N-terminal truncated isoforms of p73 (DeltaNp73) act as dominant-negative inhibitors of wild-type p53 and TAp73 and result in tumour growth in nude mice.
  • AIMS: To detect DeltaNp73 expression in 24 benign prostatic hyperplasia samples, 33 prostate carcinomas, and five normal samples and to evaluate the relation between DeltaNp73, TAp73 concentrations, and the clinicopathological characteristics of patients with prostate cancer.
  • RESULTS: A significant increase of DeltaNp73 was seen in 20 of 33 carcinomas and 17 of 24 benign prostate hyperplasia tissues, but in none of the normal samples.
  • [MeSH-major] Biomarkers, Tumor / metabolism. DNA-Binding Proteins / metabolism. Nuclear Proteins / metabolism. Prostatic Neoplasms / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Aged. Blotting, Western. Disease Progression. Humans. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction / methods. Prostate / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Hyperplasia / pathology. Reverse Transcriptase Polymerase Chain Reaction / methods. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Death Differ. 2001 Dec;8(12):1213-23 [11753569.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3369-73 [8324747.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):165-70 [11801554.001]
  • [Cites] Trends Genet. 2002 Feb;18(2):90-5 [11818141.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):636-41 [11830511.001]
  • [Cites] Cell Death Differ. 2002 Mar;9(3):343-5 [11859417.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3598-602 [12097259.001]
  • [Cites] Oncogene. 2002 Jul 18;21(31):4715-27 [12101410.001]
  • [Cites] J Exp Med. 2002 Sep 16;196(6):765-80 [12235210.001]
  • [Cites] Acta Oncol. 2002;41(6):550-5 [12546528.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(2):174-81 [12806379.001]
  • [Cites] Jpn J Clin Oncol. 2003 May;33(5):215-20 [12865464.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):162-6 [14618632.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1337-41 [15138575.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6905-11 [15501968.001]
  • [Cites] Cell. 1997 Aug 22;90(4):809-19 [9288759.001]
  • [Cites] Nature. 1997 Sep 11;389(6647):191-4 [9296498.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2076-7 [9605745.001]
  • [Cites] J Natl Cancer Inst. 1999 Jul 7;91(13):1154-8 [10393724.001]
  • [Cites] Nat Genet. 2000 Dec;26(4):464-9 [11101847.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):81-8 [11205922.001]
  • [Cites] Brain Pathol. 2001 Jul;11(3):296-305 [11414472.001]
  • [Cites] Ann Oncol. 2001 Jul;12(7):981-6 [11521806.001]
  • [Cites] J Natl Cancer Inst. 1992 Jun 3;84(11):883-7 [1350643.001]
  • [Cites] Chin Med J (Engl). 2000 Apr;113(4):299-302 [11775222.001]
  • (PMID = 16254107.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC1770779
  •  go-up   go-down


9. Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM: Epidemiology of intracranial meningioma. Neurosurgery; 2005 Dec;57(6):1088-95; discussion 1088-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are the most frequently reported primary intracranial neoplasms, accounting for approximately 25% of all such lesions diagnosed in the United States.
  • Few studies have examined the risk factors associated with a diagnosis of meningioma with two categories of exposure, hormones (both endogenous and exogenous) and radiation, most strongly associated with meningioma risk.
  • Recent legislation passed in the United States (The Benign Brain Tumor Cancer Registries Amendment Act [H.R.
  • 5204]) mandates registration of benign brain tumors such as meningioma.
  • The increased emphasis on research dedicated to the study of brain tumors coupled with the advent of new tools in genetic and molecular epidemiology make the current era an ideal time to advance knowledge for intracranial meningioma.

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16331155.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R25 CA089017; United States / NCI NIH HHS / CA / 5R25-CA089017-03; United States / NCI NIH HHS / CA / P50-CA097257; United States / NCI NIH HHS / CA / R01-CA52689
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 76
  •  go-up   go-down


10. McCall T, Chin SS, Salzman KL, Fults DW: Tuberous sclerosis: a syndrome of incomplete tumor suppression. Neurosurg Focus; 2006;20(1):E3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tuberous sclerosis: a syndrome of incomplete tumor suppression.
  • The latter is a benign brain tumor of mixed neuronal and glial origin.
  • [MeSH-major] Hamartoma / complications. Tuberous Sclerosis / etiology. Tuberous Sclerosis / genetics. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Animals. Brain Neoplasms / complications. Brain Neoplasms / genetics. Humans. Models, Biological

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16459993.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein; 4JG2LF96VF / tuberous sclerosis complex 2 protein
  • [Number-of-references] 92
  •  go-up   go-down


11. Lau EW, Drummond KJ, Ware RE, Drummond E, Hogg A, Ryan G, Grigg A, Callahan J, Hicks RJ: Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour. J Clin Neurosci; 2010 Jan;17(1):43-9
Hazardous Substances Data Bank. L-TYROSINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour.
  • The aim of this prospective pilot study in patients with suspected or known brain tumour was to establish the diagnostic value of O-(2-[(18)F]-fluoroethyl)-L-tyrosine (FET) positron emission tomography (PET) when compared to fluorine-18 fluorodeoxyglucose (FDG) PET.
  • Benign pathology included two encephalitis and one cortical dysplasia.
  • FET PET is more accurate than FDG PET for detecting malignant brain lesions, especially low-grade gliomas.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods. Radioisotopes. Tyrosine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Brain / pathology. Brain / physiopathology. Brain / radionuclide imaging. Diagnosis, Differential. Diagnostic Errors / prevention & control. Female. Glioma / metabolism. Glioma / pathology. Glioma / radionuclide imaging. Humans. Lymphoma / metabolism. Lymphoma / pathology. Lymphoma / radionuclide imaging. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Reproducibility of Results. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20004582.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / O-(2-((18)F)fluoroethyl)-L-tyrosine; 0 / Radioisotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 42HK56048U / Tyrosine
  •  go-up   go-down


12. Wöhrer A, Waldhör T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mösenbacher U, Kiefer A, Maier H, Motz R, Reiner-Concin A, Richling B, Idriceanu C, Scarpatetti M, Sedivy R, Bankl HC, Stiglbauer W, Preusser M, Rössler K, Hainfellner JA: The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol; 2009 Dec;95(3):401-411
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry.
  • In Austria, registration of malignant brain tumours is legally mandatory, whereas benign and borderline tumours are not reported.
  • The Austrian Brain Tumour Registry (ABTR) was initiated under the auspices of the Austrian Society of Neuropathology for the registration of malignant and non-malignant brain tumours.
  • All Austrian neuropathology units involved in brain tumour diagnostics contribute data on primary brain tumours.
  • In 2005, we registered a total of 1,688 newly diagnosed primary brain tumours in a population of 8.2 million inhabitants with an overall age-adjusted incidence rate of 18.1/100,000 person-years.
  • Comparison with the Central Brain Tumor Registry of the United States (CBTRUS) database showed high congruency of findings.
  • The ABTR model led by neuropathologists in collaboration with epidemiologists and the Austrian National Cancer Registry presents a cooperative way to establish a population-based brain tumour registry with high quality data.
  • The continued operation of ABTR will aid in monitoring changes in incidence and in identifying regional disease clusters or geographic variations in brain tumour morbidity/mortality.
  • [MeSH-major] Brain Neoplasms / epidemiology. Glioblastoma / epidemiology. Registries / standards. Registries / statistics & numerical data
  • [MeSH-minor] Adenoma / epidemiology. Adenoma / pathology. Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Austria / epidemiology. Child. Child, Preschool. Ependymoma / epidemiology. Ependymoma / pathology. Female. Geographic Information Systems. Humans. Incidence. Male. Meningeal Neoplasms / epidemiology. Meningeal Neoplasms / pathology. Middle Aged. Oligodendroglioma / epidemiology. Oligodendroglioma / pathology. Reproducibility of Results. Sex Distribution. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562257.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Grund S, Schittenhelm J, Roser F, Tatagiba M, Mawrin C, Kim YJ, Bornemann A: The microglial/macrophagic response at the tumour-brain border of invasive meningiomas. Neuropathol Appl Neurobiol; 2009 Feb;35(1):82-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The microglial/macrophagic response at the tumour-brain border of invasive meningiomas.
  • AIMS: Little is known about the immune response of the brain to invasive meningiomas.
  • The present study was based upon the hypothesis that the microglial/macrophagic response towards brain-invasive meningiomas is dependent on the intactness of the pial-glial basement membrane.
  • METHODS: We immunostained sections from 40 brain-invasive meningiomas that were graded according to World Health Organization (WHO) 2007 criteria.
  • Thirty-three tumours were histologically WHO grade II (18, 'otherwise benign', and 15, 'otherwise atypical'), and seven, grade III.
  • RESULTS: Twenty-five per cent (10/40) meningiomas (1/18 WHO grade II 'otherwise benign', 3/15 grade II 'otherwise atypical' and 6/7 WHO grade III) contained microglial/macrophagic cells at the tumour-brain border.
  • The monocytic response was of two kinds: one consisted of a dense layer of mononuclear cells at the tumour-brain border in nine cases, the other of an elevated number of microglial cells expressing CD14 or CD163 (two cases).
  • CONCLUSIONS: The immune response at the tumour-brain interface correlates with the absence of the pial-glial BM and with malignancy grade.
  • It remains to be established whether the mononuclear cells at the tumour-brain border are native microglia or blood-derived macrophages.
  • [MeSH-major] Brain / immunology. Brain Neoplasms / immunology. Macrophages / immunology. Meningioma / immunology. Microglia / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19187060.001).
  • [ISSN] 1365-2990
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD14; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD163 antigen; 0 / CD68 antigen, human; 0 / Receptors, Cell Surface
  •  go-up   go-down


14. Blackburn W, Leung G, Morash C: Brain Tumour Foundation Award 2007. Glomus jugulare tumours: are they really so benign? Can J Neurosci Nurs; 2007;29(2):21-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain Tumour Foundation Award 2007. Glomus jugulare tumours: are they really so benign?
  • Glomus jugulare tumours are rare, hypervascular and usually benign tumours involving the skull base.
  • Diagnosis can be significantly delayed due to the slow and insidious clinical presentation.
  • These complications are linked to the location and vascular nature of the tumour.
  • [MeSH-major] Glomus Jugulare Tumor / diagnosis. Glomus Jugulare Tumor / therapy. Nurse's Role. Perioperative Care
  • [MeSH-minor] Angiography, Digital Subtraction. Diagnosis, Differential. Early Diagnosis. Embolization, Therapeutic / methods. Embolization, Therapeutic / nursing. Female. Headache / etiology. Humans. Magnetic Resonance Imaging. Middle Aged. Patient Care Team / organization & administration. Prevalence. Prognosis. Rare Diseases. Risk Factors. Tinnitus / etiology. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18240628.001).
  • [ISSN] 1913-7176
  • [Journal-full-title] Canadian journal of neuroscience nursing
  • [ISO-abbreviation] Can J Neurosci Nurs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Canada
  • [Number-of-references] 42
  •  go-up   go-down


15. McCarthy BJ, Schellinger KA, Propp JM, Kruchko C, Malmer B: A case for the worldwide collection of primary benign brain tumors. Neuroepidemiology; 2009;33(3):268-75
figshare. supplemental materials - Supporting Data and Materials for the article .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case for the worldwide collection of primary benign brain tumors.
  • BACKGROUND: Incidence data on malignant tumors are reported by the International Agency for Research on Cancer, with 189,485 new malignant brain tumors globally in 2002.
  • However, collection and reporting of benign brain tumors are not universal.
  • The objective here is to encourage the collection of primary benign brain tumors worldwide.
  • METHODS: Worldwide numbers of primary benign brain tumors were estimated through published articles and cancer registry reports presenting directly or indirectly reported benign incidence rates or frequencies for regions or countries.
  • RESULTS: An estimated 186,678 benign brain tumors were diagnosed worldwide in 2002.
  • The estimated numbers of benign brain tumors were higher in females than males (105,918 vs. 80,759).
  • Since many countries do not report primary benign brain tumors, the incidence rate estimates vary significantly by region.
  • CONCLUSIONS: This is the first survey to assess worldwide numbers of benign brain tumors.
  • However, the estimated number of benign brain tumors approximately equals, and could exceed, the number of malignant brain tumors globally.
  • Registration of primary benign brain histologies in different geographical areas and ethnicities could provide clues to the underlying causes of these tumors.
  • [MeSH-major] Brain Neoplasms / epidemiology. Global Health

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - International Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19648771.001).
  • [ISSN] 1423-0208
  • [Journal-full-title] Neuroepidemiology
  • [ISO-abbreviation] Neuroepidemiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 57
  •  go-up   go-down


16. Jalali R, Budrukkar A, Sarin R, Sharma DS: High precision conformal radiotherapy employing conservative margins in childhood benign and low-grade brain tumours. Radiother Oncol; 2005 Jan;74(1):37-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High precision conformal radiotherapy employing conservative margins in childhood benign and low-grade brain tumours.
  • BACKGROUND AND PURPOSE: To report local control and follow up outcome data of high precision conformal radiotherapy in childhood brain tumours.
  • MATERIALS AND METHODS: Between December 1999 and December 2002, 26 children (17 boys and 9 girls, median age 11.5 years) with incompletely excised or recurrent benign and low-grade brain tumours [13 craniopharyngiomas, 11 low-grade gliomas (LGG) and 2 others] were treated with three-dimensional (3D) conformal radiotherapy (CRT) (12 patients) and stereotactic conformal radiotherapy (SCRT) (14 patients).
  • Gross tumour volume (GTV) included neuro-imaging based visible tumour and/or resected tumour bed.
  • CONCLUSION: High-precision conformal techniques delivering irradiation to a computer generated target volume employing 7-10 mm 3D margins beyond the visible tumour and/or resected tumour bed appear to be safe in children with incompletely resected or recurrent benign and low-grade brain tumours, based on these data.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Craniopharyngioma / radiotherapy. Glioma / radiotherapy. Radiotherapy, Conformal
  • [MeSH-minor] Adolescent. Adult. Brain Diseases / etiology. Child. Child, Preschool. Combined Modality Therapy. Cysts / etiology. Dose Fractionation. Female. Humans. Male. Radiation Injuries. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15683667.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


17. Duclos C, Bonnin N, Merlin E, Viorel A, Lacombe P, Dalens H, Chiambaretta F, Deméocq F, Chazal J, Kanold J: [Benign but not harmless intracranial hypertension: a case report]. Arch Pediatr; 2010 Dec;17(12):1677-81
Hazardous Substances Data Bank. ACETAZOLAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign but not harmless intracranial hypertension: a case report].
  • Benign intracranial hypertension (BIH) is characterized as an intracranial pressure increase occurring in the absence of brain tumour, sinus thrombosis or hydrocephaly.
  • Cerebrospinal fluid pressure was 70cm water, without enlargement of the cerebral ventricles.
  • This case shows that BIH, which is not a well-known disorder, is incorrectly referred to as benign: both prompt diagnosis and proper management are of major importance.

  • Genetic Alliance. consumer health - Intracranial Hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 21087845.001).
  • [ISSN] 1769-664X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Diuretics; O3FX965V0I / Acetazolamide
  •  go-up   go-down


18. Tun K, Celikmez RC, Okutan O, Gurcan O, Beskonakli E: Dermoid tumour of the lateral wall of the cavernous sinus. J Clin Neurosci; 2008 Jul;15(7):820-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoid tumour of the lateral wall of the cavernous sinus.
  • Congenital intracranial dermoid tumors are very rare.
  • Dermoid tumors originating from the cavernous sinus are usually interdural and thus, presentation with ophthalmoplegia is uncommon.
  • They are congenital benign tumors and are believed to originate from ectopic inclusion of epithelial cells during closure of the neural tube during embryonic development.
  • [MeSH-major] Brain Neoplasms / pathology. Cavernous Sinus / pathology. Cavernous Sinus Thrombosis / etiology. Cavernous Sinus Thrombosis / pathology. Dermoid Cyst / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Neurosci. 2009 Aug;16(8):1115
  • (PMID = 18462942.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


19. Asioli S, Senetta R, Maldi E, D'Ambrosio E, Satolli MA, Bussolati G, Cassoni P: "Benign" metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung. Virchows Arch; 2007 May;450(5):591-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Benign" metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung.
  • Lung "metastases" of benign meningiomas are rarely described events of biological and clinical interest.
  • Anamnesis revealed that the patient underwent a surgical resection of cerebral meningioma 12 years before.
  • The morphological and immunohistochemical features of this lesion, together with the similarity with the original cerebral tumour and its indolent evolution, led to a final diagnosis of "benign" meningioma metastatic to the lung.
  • They represent a typical example of "benign" tumours that may implant to the lung similar to other tumours, definitely considered benign but reported to rarely present unusual secondary localization.
  • [MeSH-major] Brain Neoplasms / pathology. Lung Neoplasms / secondary. Meningioma / secondary
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Humans. Neoplasm Metastasis / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431673.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


20. Montano N, Doglietto F, Lauriola L, Signorelli F, Pallini R: Solitary fibrous tumour of the IV ventricle. Br J Neurosurg; 2010 Aug;24(4):495-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumour of the IV ventricle.
  • BACKGROUND: Solitary Fibrous Tumour (SFT) is a rare tumour occurring mainly in the pleural cavity, with less than 100 cases reported in the Central Nervous System, where it typically presents as a meningeal-based lesion.
  • Brain magnetic resonance imaging revealed a contrast enhancing, space occupying lesion in the fourth ventricle, with no dural attachment.
  • CONCLUSION: Although uncommon, SFT should always be included in the differential diagnosis of intraventricular tumours.
  • SFTs of the fourth ventricle are usually benign tumours.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Solitary Fibrous Tumors / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20726760.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Brain O, Brown LH, Suvarna S, Chapman R: Markedly elevated CA19-9 associated with benign ovarian cyst and ascites. BMJ Case Rep; 2009;2009
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Markedly elevated CA19-9 associated with benign ovarian cyst and ascites.
  • A malignant cause appeared likely, cross-sectional imaging was arranged and tumour markers sent.
  • At laparoscopy a benign ruptured ovarian cyst was detected, and ascites drained.
  • This case demonstrates how tumour markers may be misleading in the context of diagnostics, and is the highest reported example of CA19-9 rise in the context of benign ascites and benign ovarian pathology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Obstet Gynaecol. 2007 Jan;27(1):96-7 [17365480.001]
  • [Cites] Gynecol Obstet Invest. 1989;28(3):165-8 [2680806.001]
  • [Cites] Intern Emerg Med. 2007 Jun;2(2):88-94 [17622496.001]
  • [Cites] Science. 1981 Apr 3;212(4490):53-5 [6163212.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1616-21 [11813585.001]
  • [Cites] Int J Gynaecol Obstet. 2005 Dec;91(3):262-3 [16168992.001]
  • [Cites] Oncology. 2006;70(4):255-64 [16899980.001]
  • (PMID = 21686409.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3030236
  •  go-up   go-down


22. Taranath A, Lam A, Wong CK: Desmoplastic infantile ganglioglioma: a questionably benign tumour. Australas Radiol; 2005 Oct;49(5):433-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic infantile ganglioglioma: a questionably benign tumour.
  • Desmoplastic infantile ganglioglioma is a rare intracranial tumour of childhood that involves the cerebral cortex and the leptomeninges.
  • Pathologically, this rare intracranial tumour shows glial and ganglionic differentiation, accompanied by an extreme desmoplastic reaction.
  • These are low-grade neoplasms that are questionably benign.
  • [MeSH-major] Brain Neoplasms / pathology. Ganglioglioma / pathology. Magnetic Resonance Imaging. Spinal Cord Neoplasms / pathology


23. Liu J, Zheng S, Yu JK, Zhang JM, Chen Z: Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor. J Zhejiang Univ Sci B; 2005 Jan;6(1):4-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor.
  • To screen and evaluate protein biomarkers for the detection of gliomas (Astrocytoma grade I-IV) from healthy individuals and gliomas from brain benign tumors by using surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) coupled with an artificial neural network (ANN) algorithm.
  • SELDI-TOF-MS protein fingerprinting of serum from 105 brain tumor patients and healthy individuals, included 28 patients with glioma (Astrocytoma I-IV), 37 patients with brain benign tumor, and 40 age-matched healthy individuals.
  • An accuracy of 95.7%, sensitivity of 88.9%, specificity of 100%, positive predictive value of 90% and negative predictive value of 100% were obtained in a blinded test set comparing gliomas patients with healthy individuals; an accuracy of 86.4%, sensitivity of 88.9%, specificity of 84.6%, positive predictive value of 90% and negative predictive value of 85.7% were obtained when patient's gliomas was compared with benign brain tumor.
  • The high sensitivity and specificity achieved by the use of selected biomarkers showed great potential application for the discrimination of gliomas patients from healthy individuals and gliomas from brain benign tumors.
  • [MeSH-major] Astrocytoma / blood. Astrocytoma / diagnosis. Biomarkers, Tumor / blood. Brain Neoplasms / blood. Brain Neoplasms / diagnosis. Diagnosis, Computer-Assisted / methods. Neoplasm Proteins / blood. Peptide Mapping / methods

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Pain. 2003 Apr;102(3):251-6 [12670666.001]
  • [Cites] Curr Med Chem. 2003 May;10(10):831-43 [12678686.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s [12743135.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):267-79 [12781425.001]
  • [Cites] Curr Pharm Biotechnol. 2004 Feb;5(1):45-67 [14965209.001]
  • [Cites] Curr Opin Biotechnol. 2004 Feb;15(1):24-30 [15102462.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1164-77 [10786889.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Bioinformatics. 2002 Mar;18(3):395-404 [11934738.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1160-9 [12142368.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2541-52 [12171882.001]
  • (PMID = 15593384.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Letter; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC1390751
  •  go-up   go-down


24. Panagopoulos AT, Lancellotti CL, Veiga JC, de Aguiar PH, Colquhoun A: Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. J Neurooncol; 2008 Aug;89(1):73-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas.
  • Most meningiomas are benign tumours of arachnoidal origin, although a small number have high proliferative rates and invasive properties which complicate complete surgical resection and are associated with increased recurrence rates.
  • Few prognostic indicators exist for meningiomas and further research is necessary to identify factors that influence tumour invasion, oedema and recurrence.
  • Paraffin sections from 25 intracranial meningiomas were analysed for expression of the proteins vascular endothelial growth factor (VEGF), VEGF receptors Flt1 and Flk1, E-cadherin, metalloproteinases 2 and 9 (MMP2, MMP9), CD44, receptor for hyaluronic acid-mediated motility (RHAMM), hyaluronic acid (HA), CD45, cyclooxygenase 2 (COX2), brain fatty acid binding protein (BFABP), Ki67, and proliferating cell nuclear antigen (PCNA).
  • COX2 expression increased with increasing with tumour grade and correlated with Ki67, PCNA, MI, MVD, and BFABP.
  • In conclusion Ki67, PCNA, MI, MVD, BFABP, and COX2 were significantly correlated with meningioma tumour grade and with each other.
  • These findings, by correlating both intracellular fatty acid transport and eicosanoid metabolism with tumour proliferation, as determined by Ki67 labelling and mitotic index, suggest fatty acids are involved in the progression of meningiomas.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / biosynthesis. Fatty Acids / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Neoplasm Proteins / biosynthesis. Neovascularization, Pathologic / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18418552.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / Eicosanoids; 0 / Fatty Acids; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Proliferating Cell Nuclear Antigen; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


25. Shrieve DC: Basic principles of radiobiology applied to radiotherapy of benign intracranial tumors. Neurosurg Clin N Am; 2006 Apr;17(2):67-78, v
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basic principles of radiobiology applied to radiotherapy of benign intracranial tumors.
  • The use of ionizing radiation in the treatment of benign intracranial tumors may involve one of several types of ionizing radiation given as single-fraction radiosurgery or fractionated radiotherapy.
  • This article discusses the basic radiobiologic principles applicable to radiotherapy of benign brain tumors.
  • [MeSH-major] Brain / radiation effects. Brain Neoplasms / radiotherapy. Radiobiology / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793500.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Gávai M, Váradi V, Belics Z, Papp Z: [Fetal ischaemic brain injury in the second trimester of pregnancy]. Orv Hetil; 2006 Aug 20;147(33):1567-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fetal ischaemic brain injury in the second trimester of pregnancy].
  • Each of these factors is supposed to be a major precursor for neurological and intellectual impairment, and cerebral palsy (CP) in later life.
  • Antenatal rather than intrapartum factors are now emerging as the major determinants of cerebral palsy.
  • In this case report maternal trauma, benign tumour, severe anaemia and fetal cerebral vascular malformation are supposed as causative factors in intrauterine periventricular leukomalacia resulting from hypoxic-ischaemic injury.
  • [MeSH-major] Brain Ischemia / complications. Leukomalacia, Periventricular / etiology. Pregnancy Trimester, Second

  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17037679.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


27. Yang Y, Shao N, Luo G, Li L, Nilsson-Ehle P, Xu N: Relationship between PTEN gene expression and differentiation of human glioma. Scand J Clin Lab Invest; 2006;66(6):469-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor-adjacent normal tissues and benign brain tumors were used as controls.
  • RESULTS: PTEN mRNA levels were significantly lower in the glioma tissues than in the benign brain tumors and tumor-adjacent normal tissues, whereas there were no statistical differences between benign brain tumor and the tumor-adjacent normal tissues.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Glioma / genetics. Glioma / pathology. PTEN Phosphohydrolase / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / genetics. Astrocytoma / pathology. Child. Female. Gene Expression. Genes, Tumor Suppressor. Glioblastoma / genetics. Glioblastoma / pathology. Glyceraldehyde-3-Phosphate Dehydrogenases / genetics. Humans. Male. Meningioma / genetics. Meningioma / pathology. Middle Aged. Mutation. Neuroma, Acoustic / genetics. Neuroma, Acoustic / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17000554.001).
  • [ISSN] 0036-5513
  • [Journal-full-title] Scandinavian journal of clinical and laboratory investigation
  • [ISO-abbreviation] Scand. J. Clin. Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


28. Mauermann ML, Amrami KK, Kuntz NL, Spinner RJ, Dyck PJ, Bosch EP, Engelstad J, Felmlee JP, Dyck PJ: Longitudinal study of intraneural perineurioma--a benign, focal hypertrophic neuropathy of youth. Brain; 2009 Aug;132(Pt 8):2265-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Longitudinal study of intraneural perineurioma--a benign, focal hypertrophic neuropathy of youth.
  • We conclude intraneural perineurioma is a benign hypertrophic (non onion bulb) peripheral nerve tumour that presents insidiously in young people and is motor predominant with mild sensory involvement.
  • Diagnosis of this condition requires clinical suspicion, imaging, targeted fascicular biopsy of the lesion and expertise of nerve pathologists.
  • Because intensive evaluation is needed for diagnosis, intraneural perineurioma is probably under-recognized.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1982 Oct;106(10):534-7 [6289772.001]
  • [Cites] Neurosurgery. 1981 Mar;8(3):397-9 [6264342.001]
  • [Cites] Clin Neuropathol. 1984 Sep-Oct;3(5):228-30 [6094068.001]
  • [Cites] Neurosurgery. 1986 Jul;19(1):134-8 [3748334.001]
  • [Cites] Am J Surg Pathol. 1988 Sep;12(9):678-83 [3046395.001]
  • [Cites] Neurosurgery. 1988 Aug;23(2):218-21 [2847076.001]
  • [Cites] Hum Pathol. 1988 Dec;19(12):1455-7 [2847973.001]
  • [Cites] Stroke. 1988 Dec;19(12):1497-500 [3201508.001]
  • [Cites] Acta Neuropathol. 1989;77(5):514-8 [2655369.001]
  • [Cites] Muscle Nerve. 1991 Apr;14(4):335-41 [1851247.001]
  • [Cites] Am J Surg Pathol. 1992 Aug;16(8):756-63 [1497116.001]
  • [Cites] Pathol Res Pract. 1992 Aug;188(6):815-6 [1332008.001]
  • [Cites] Muscle Nerve. 1992 Dec;15(12):1364-8 [1470202.001]
  • [Cites] J Clin Neurophysiol. 1993 Jan;10(1):14-27 [8458992.001]
  • [Cites] Mayo Clin Proc. 1994 Aug;69(8):747-8 [8035630.001]
  • [Cites] Am J Clin Pathol. 1995 Jun;103(6):696-704 [7785653.001]
  • [Cites] Neurosurgery. 1998 Jul;43(1):78-83 [9657192.001]
  • [Cites] Muscle Nerve. 1999 Jan;22(1):28-36 [9883854.001]
  • [Cites] Neurology. 1999 Jan 15;52(2):389-92 [9932963.001]
  • [Cites] J Neurol Sci. 1964 Jul-Aug;1(4):340-7 [14192576.001]
  • [Cites] J Hand Surg Am. 2005 Jul;30(4):820-5 [16039379.001]
  • [Cites] Arch Pathol Lab Med. 2007 Apr;131(4):625-36 [17425397.001]
  • [Cites] Neurology. 2007 Jul 3;69(1):84-90 [17606886.001]
  • [Cites] Arch Pathol Lab Med. 2007 Sep;131(9):1382-92 [17824794.001]
  • [Cites] Muscle Nerve. 2007 Nov;36(5):715-20 [17471567.001]
  • [Cites] Plast Reconstr Surg. 2000 May;105(6):2089-91 [10839408.001]
  • [Cites] J Hand Surg Br. 2001 Apr;26(2):168-70 [11281674.001]
  • [Cites] J Neurosurg. 2001 May;94(5):811-5 [11354415.001]
  • [Cites] Can J Neurol Sci. 2002 Aug;29(3):258-66 [12195616.001]
  • [Cites] Med Oral. 2004 Jan-Feb;9(1):64-8 [14704619.001]
  • [Cites] J Child Neurol. 2004 Jan;19(1):71-5 [15032391.001]
  • [Cites] Pathol Int. 2004 May;54(5):371-5 [15086844.001]
  • [Cites] Pathology. 2004 Aug;36(4):309-15 [15370128.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1966 Feb;29(1):80-4 [4286389.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1973 Dec;36(6):991-6 [4772730.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1974 Jan;37(1):76-81 [4360401.001]
  • [Cites] Mayo Clin Proc. 1975 Nov;50(11):621-37 [1186294.001]
  • [Cites] Surg Neurol. 1977 Mar;7(3):131-4 [191946.001]
  • [Cites] Muscle Nerve. 1980 Sep-Oct;3(5):403-12 [6775221.001]
  • [Cites] Ann Neurol. 1980 Dec;8(6):590-6 [7212646.001]
  • [Cites] Arch Pathol Lab Med. 1984 Jul;108(7):557-60 [6329127.001]
  • (PMID = 19567701.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS36979
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2724918
  •  go-up   go-down


29. Sundgren PC, Cao Y: Brain irradiation: effects on normal brain parenchyma and radiation injury. Neuroimaging Clin N Am; 2009 Nov;19(4):657-68
MedlinePlus Health Information. consumer health - Diagnostic Imaging.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain irradiation: effects on normal brain parenchyma and radiation injury.
  • Radiation therapy is a major treatment modality for malignant and benign brain tumors.
  • Concerns of radiation effects on the brain tissue and neurocognitive function and quality of life increase as survival of patients treated for brain tumors improves.
  • In this article, the clinical and neurobehavioral symptoms and signs of radiation-induced brain injury, possible histopathology, and the potential of functional, metabolic, and molecular imaging as a biomarker for assessment and prediction of neurotoxicity after brain irradiation and imaging findings in radiation necrosis are discussed.
  • [MeSH-major] Brain / radiation effects. Brain Injuries / diagnosis. Brain Injuries / etiology. Diagnostic Imaging / methods. Radiation Injuries / diagnosis. Radiation Injuries / etiology. Radiotherapy, Conformal / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19959011.001).
  • [ISSN] 1557-9867
  • [Journal-full-title] Neuroimaging clinics of North America
  • [ISO-abbreviation] Neuroimaging Clin. N. Am.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS064973
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS167505; NLM/ PMC5000393
  •  go-up   go-down


30. Aoki T, Tashiro Y, Fujita K, Kajiwara M, Matsuda Y: [The evaluation of preoperative and postoperative frontal lobe functions in three operative cases of meningioma]. No Shinkei Geka; 2006 Feb;34(2):161-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report three cases of frontal meningioma with their pre- and post-operative evaluations of higher brain functions, especially of frontal lobe functions.
  • All of the cases showed the improvement of the frontal lobe functions after the tumor removal.
  • The evaluations of frontal lobe functions in benign brain tumors such as a meningioma are reported only in a few cases.
  • The evaluations of frontal lobe functions in the operative cases of benign brain tumors provide many interesting and valuable informations about frontal lobe functions.
  • So we must be more interest in evaluations in higher brain functions and accumulate cases for the further analysis of higher brain functions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485561.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


31. Kreil W, Luggin J, Fuchs I, Weigl V, Eustacchio S, Papaefthymiou G: Long term experience of gamma knife radiosurgery for benign skull base meningiomas. J Neurol Neurosurg Psychiatry; 2005 Oct;76(10):1425-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term experience of gamma knife radiosurgery for benign skull base meningiomas.
  • OBJECTIVES: As most reports on the gamma knife have related only to short or mid-term results, we decided to evaluate the effectiveness and toxicity of radiosurgical treatment for benign skull base meningiomas in 200 patients with a follow up of 5-12 years to define the role of gamma knife radiosurgery (GKRS) for basal meningiomas and to provide further data for comparison with other treatment options.
  • Tumour volumes ranged from 0.38 to 89.8 cm3 (median 6.5 cm3), and doses of 7-25 Gy (median 12 Gy) were given to the tumour borders at covering isodose volume curves (range 20-80%, median 45%).
  • Worsening was transient in seven patients (3.5%) and unrelated to tumour or treatment in one (0.5%).
  • Because of the excellent long term tumour control rate and low morbidity associated with GKRS, this treatment option should be used more frequently in the therapeutic management of benign skull base meningiomas.
  • [MeSH-major] Meningioma / surgery. Radiosurgery / instrumentation. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Microsurgery / instrumentation. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Postoperative Complications / epidemiology. Salvage Therapy / methods. Survival Rate. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stereotact Funct Neurosurg. 1996;66 Suppl 1:112-20 [9032851.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] Surg Neurol. 1997 Apr;47(4):371-9 [9122842.001]
  • [Cites] Neurosurgery. 1997 Oct;41(4):767-74; discussion 774-5 [9316037.001]
  • [Cites] Minim Invasive Neurosurg. 1997 Sep;40(3):87-90 [9359085.001]
  • [Cites] Neurosurgery. 1997 Nov;41(5):1019-25; discussion 1025-7 [9361055.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):43-50 [9420071.001]
  • [Cites] Neurosurgery. 1998 Mar;42(3):437-43; discussion 443-5 [9526975.001]
  • [Cites] Stereotact Funct Neurosurg. 1998 Oct;70 Suppl 1:19-32 [9782232.001]
  • [Cites] Stereotact Funct Neurosurg. 1998 Oct;70 Suppl 1:33-40 [9782233.001]
  • [Cites] Surg Neurol. 1999 Mar;51(3):268-73 [10086490.001]
  • [Cites] Neurosurg Clin N Am. 1999 Apr;10(2):271-80 [10099092.001]
  • [Cites] Surg Neurol. 1999 Apr;51(4):412-9; discussion 419-20 [10199295.001]
  • [Cites] J Neurosurg. 1999 May;90(5):823-7 [10223446.001]
  • [Cites] J Neurosurg. 2000 Jan;92(1 Suppl):71-80 [10616061.001]
  • [Cites] Stereotact Funct Neurosurg. 1999;72 Suppl 1:67-72 [10681693.001]
  • [Cites] Neurosurgery. 2000 Mar;46(3):567-74; discussion 574-5 [10719852.001]
  • [Cites] Stereotact Funct Neurosurg. 1999;73(1-4):72-8 [10853105.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(6):647-52; discussion 652-3 [10949439.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:107-12 [11143226.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:219-22 [11143252.001]
  • [Cites] J Clin Neurosci. 2001 May;8 Suppl 1:12-4 [11386818.001]
  • [Cites] Surg Neurol. 2001 Jun;55(6):325-31 [11483185.001]
  • [Cites] Acta Neurochir (Wien). 2001 Nov;143(11):1141-52 [11731865.001]
  • [Cites] Acta Neurochir Suppl. 2002;84:71-6 [12379007.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):101-11 [15093905.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Oct;17(4):879-85 [2777680.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Apr;18(4):755-61 [2108937.001]
  • [Cites] J Neurosurg. 1999 Jul;91(1):44-50 [10389879.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):1021-6 [2120162.001]
  • [Cites] J Neurosurg. 1991 Apr;74(4):552-9 [2002367.001]
  • [Cites] Acta Neurochir (Wien). 1992;118(1-2):27-32 [1414527.001]
  • [Cites] Neurosurgery. 1992 Nov;31(5):813-28; discussion 828 [1436406.001]
  • [Cites] Neurosurgery. 1993 May;32(5):699-704; discussion 704-5 [8492844.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Stereotact Funct Neurosurg. 1993;61 Suppl 1:23-9 [8115752.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):245-51 [8027808.001]
  • [Cites] J Neurosurg. 1994 Dec;81(6):860-8 [7965116.001]
  • [Cites] J Neurosurg. 1996 Jan;84(1):20-8 [8613831.001]
  • [Cites] Neurosurgery. 1995 Jul;37(1):1-9; discussion 9-10 [8587667.001]
  • [Cites] Br J Neurosurg. 1996 Feb;10(1):59-68 [8672260.001]
  • [Cites] Surg Neurol. 1996 Sep;46(3):272-8; discussion 278-9 [8781598.001]
  • [Cites] Neurosurgery. 1996 Jul;39(1):2-7; discussion 8-9 [8805134.001]
  • [Cites] Neurosurgery. 1996 Nov;39(5):915-9; discussion 919-20 [8905745.001]
  • [Cites] Neurosurgery. 1996 Dec;39(6):1086-94; discussion 1094-5 [8938761.001]
  • [Cites] Surg Neurol. 1999 Jul;52(1):40-4; discussion 44-5 [10390171.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(5):473-80 [10392202.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):42-9 [10413154.001]
  • [Cites] Stereotact Funct Neurosurg. 1996;66 Suppl 1:129-33 [9032853.001]
  • (PMID = 16170090.001).
  • [ISSN] 0022-3050
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatr.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 56
  • [Other-IDs] NLM/ PMC1739368
  •  go-up   go-down


32. Vranic A: Antigen expression on recurrent meningioma cells. Radiol Oncol; 2010 Jun;44(2):107-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Meningiomas are intracranial brain tumours that frequently recur.
  • Recurrence rates up to 20% in 20 years for benign meningiomas, up to 80% for atypical meningiomas and up to 100% for malignant meningiomas, have been reported.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1999 Jul;91(1):93-9 [10389886.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] Neurosurgery. 2001 Mar;48(3):598-605 [11270551.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):839-44 [11702875.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):765-72 [11857311.001]
  • [Cites] Histopathology. 2003 Sep;43(3):280-90 [12940781.001]
  • [Cites] J Neurooncol. 2003 Aug-Sep;64(1-2):71-6 [12952288.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):29-37 [15015767.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1547-53 [15735044.001]
  • [Cites] Int J Biol Markers. 2005 Jan-Mar;20(1):50-9 [15832773.001]
  • [Cites] Clin Neuropathol. 2005 Jul-Aug;24(4):170-4 [16033133.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Hum Pathol. 2006 Apr;37(4):415-21 [16564915.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 May;79(5):574-80 [17766430.001]
  • [Cites] Radiol Oncol. 2010 Mar;44(1):1-12 [22933884.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Apr;30(2):178-87 [15043715.001]
  • [Cites] Am J Clin Pathol. 2003 Jan;119(1):123-8 [12520707.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jan;146(1):37-44; discussion 44 [14740263.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):285-90 [7542317.001]
  • [Cites] Clin Exp Metastasis. 1995 Jan;13(1):49-56 [7820956.001]
  • [Cites] Neurosurgery. 1993 Aug;33(2):212-7; discussion 217-8 [8367042.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):643-57 [8474655.001]
  • [Cites] Clin Exp Metastasis. 1996 Jan;14(1):27-34 [8521613.001]
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):559-67 [10100707.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • (PMID = 22933900.001).
  • [ISSN] 1318-2099
  • [Journal-full-title] Radiology and oncology
  • [ISO-abbreviation] Radiol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovenia
  • [Other-IDs] NLM/ PMC3423683
  • [Keywords] NOTNLM ; cathepsin B / cathepsin L / meningioma / proliferation index, MIB-1 antigen / recurrence / tumour markers
  •  go-up   go-down


33. Kohler C, Radpour R, Barekati Z, Asadollahi R, Bitzer J, Wight E, Bürki N, Diesch C, Holzgreve W, Zhong XY: Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer; 2009;8:105
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors.
  • METHODS: Using multiplex real-time PCR we investigated the levels of ccf nDNA and mtDNA in plasma samples from patients with malignant and benign breast tumors, and from healthy controls.
  • RESULTS: While the levels of ccf nDNA in the cancer group were significantly higher in comparison with the benign tumor group (P < 0.001) and the healthy control group (P < 0.001), the level of ccf mtDNA was found to be significantly lower in the two tumor-groups (benign: P < 0.001; malignant: P = 0.022).
  • The level of ccf nDNA was also associated with tumor-size (<2 cm vs. >2 cm<5 cm; 2250 vs. 6658; Mann-Whitney-U-Test: P = 0.034).
  • Using ROC curve analysis, we were able to distinguish between the breast cancer cases and the healthy controls using ccf nDNA as marker (cut-off: 1866 GE/ml; sensitivity: 81%; specificity: 69%; P < 0.001) and between the tumor group and the healthy controls using ccf mtDNA as marker (cut-off: 463282 GE/ml; sensitivity: 53%; specificity: 87%; P < 0.001).
  • CONCLUSION: Our data suggests that nuclear and mitochondrial ccf DNA have potential as biomarkers in breast tumor management.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Cell Nucleus / genetics. DNA, Mitochondrial / blood
  • [MeSH-minor] Case-Control Studies. Cell-Free System. Cohort Studies. Diagnosis, Differential. Female. Health. Humans. Lymph Nodes / pathology. Neoplasm Metastasis. ROC Curve. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 2006 Aug;24(8):905-8 [16900126.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):629-38 [16568452.001]
  • [Cites] BMC Cancer. 2006;6:269 [17116247.001]
  • [Cites] N Engl J Med. 2006 Dec 21;355(25):2631-9 [17182988.001]
  • [Cites] Mitochondrion. 2007 Feb-Apr;7(1-2):157-63 [17280876.001]
  • [Cites] Mitochondrion. 2007 Feb-Apr;7(1-2):53-7 [17320491.001]
  • [Cites] Acta Paediatr. 2007 May;96(5):644-7 [17376185.001]
  • [Cites] Int J Biol Markers. 2007 Apr-Jun;22(2):95-9 [17549664.001]
  • [Cites] Arch Gynecol Obstet. 2007 Oct;276(4):327-31 [17431649.001]
  • [Cites] Prostate. 2008 Mar 1;68(4):408-17 [18196528.001]
  • [Cites] Clin Chem Lab Med. 2008;46(3):311-7 [18254709.001]
  • [Cites] JAMA. 2008 May 14;299(18):2151-63 [18477782.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2A):921-5 [18507037.001]
  • [Cites] Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Jun;16(3):699-703 [18549658.001]
  • [Cites] Int J Biol Markers. 2008 Apr-Jun;23(2):69-73 [18629778.001]
  • [Cites] DNA Cell Biol. 2008 Aug;27(8):415-21 [18694299.001]
  • [Cites] Nat Med. 2008 Sep;14(9):985-90 [18670422.001]
  • [Cites] Obstet Gynecol. 2008 Oct;112(4):843-50 [18827127.001]
  • [Cites] Ann N Y Acad Sci. 2008 Aug;1137:175-9 [18837944.001]
  • [Cites] Cytokine. 2008 Oct;44(1):65-9 [18691902.001]
  • [Cites] Expert Rev Neurother. 2008 Dec;8(12):1841-52 [19086880.001]
  • [Cites] Neuroimage. 2009 Jun;46(2):394-410 [19236926.001]
  • [Cites] Clin Chem. 2000 Dec;46(12):1903-6 [11106320.001]
  • [Cites] Lancet. 2001 Jan 27;357(9252):310-1 [11214156.001]
  • [Cites] Swiss Med Wkly. 2001 Feb 10;131(5-6):70-4 [11383228.001]
  • [Cites] Ann N Y Acad Sci. 2001 Sep;945:138-40 [11708467.001]
  • [Cites] Clin Chim Acta. 2002 Jul;321(1-2):77-87 [12031596.001]
  • [Cites] Int J Gynaecol Obstet. 1995 Feb;48(2):187-92 [7540567.001]
  • [Cites] Lab Invest. 1996 Mar;74(3):592-9 [8600309.001]
  • [Cites] Brain Res Mol Brain Res. 1997 Dec 15;52(2):284-9 [9495550.001]
  • [Cites] Int J Cancer. 2005 Oct 10;116(6):920-4 [15856456.001]
  • [Cites] Tumour Biol. 2005 Nov-Dec;26(6):281-93 [16254457.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1564-9 [16533782.001]
  • [Cites] Prenat Diagn. 2006 Apr;26(4):362-8 [16566058.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1087-91 [17047655.001]
  • (PMID = 19922604.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Mitochondrial; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2780981
  •  go-up   go-down


34. Dhar H: Colloid cyst of third ventricle presenting as pseudoeclampsia. Arch Gynecol Obstet; 2009 Dec;280(6):1019-21
MedlinePlus Health Information. consumer health - Hydrocephalus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Emergency computed tomography scan of the brain was done which revealed colloid cyst of the third ventricle with severe acute obstructive hydrocephalus leading to irreversible brain damage and death.
  • Colloid cyst of the third ventricle is a rare benign intracranial tumour, and pregnancy often masks the symptoms.
  • High index of suspicion and early detection of tumour may be life saving.
  • [MeSH-major] Brain Neoplasms / diagnosis. Colloid Cysts / diagnosis. Hydrocephalus / diagnosis. Third Ventricle / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19319550.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


35. Sierota D, Stefanowicz J, Wierzba J, Adamkiewicz-Drozyńska E, Wybieralska-Dubaniewicz M, Kosiak W, Komasara L, Czauderna P, Izycka-Swieszewska E, Pilarska E, Birkholtz D, Stachowicz-Stencel T, Połczyńska K, Bień E, Szołkiewicz A, Stefanowicz A, Balcerska A: [Neurofibromatosis type 1 in children. Experiences of the Gdansk Paediatric Oncohaematology Centre. Preliminary results]. Med Wieku Rozwoj; 2007 Jul-Sep;11(3 Pt 2):307-12
MedlinePlus Health Information. consumer health - Health Checkup.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Neurofibromatosis type 1 (NF1) is a frequent genetic disorder of autosomal-dominant pattern.
  • In any case of NF1 without neurological symptoms, MRI of the brain and spine is carried out every 2 years.
  • Secondary symptoms and complications such as mental retardation (9 cases) and epilepsy (10 cases), cognitive disorders and learning disabilities (21), abnormalities in MRI examination (53), benign or malignant CNS tumours (9), scoliosis (99) were diagnosed.
  • In 5 patients malignant neoplasms occurred (3.4%) including: RMS--2 cases, Triton tumour--1 case, MPNST--1 case.
  • [MeSH-major] Neurofibromatosis 1 / diagnosis. Neurofibromatosis 1 / therapy. Physical Examination


36. Kaynar MY, Sanus GZ, Hnimoglu H, Kacira T, Kemerdere R, Atukeren P, Gumustas K, Canbaz B, Tanriverdi T: Expression of hypoxia inducible factor-1alpha in tumors of patients with glioblastoma multiforme and transitional meningioma. J Clin Neurosci; 2008 Sep;15(9):1036-42
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hypoxia inducible factor-1alpha in tumors of patients with glioblastoma multiforme and transitional meningioma.
  • There was no statistically significant difference between the two types of tumor (p=0.264).
  • These findings indicate that HIF-1alpha is elevated in both TM and GBM, suggesting that although hypoxia is one of the most important and powerful stimuli for HIF-1alpha elevation and consequently angiogenesis, other mechanisms may play roles in HIF-1alpha stimulation in benign brain tumors such as TM.
  • [MeSH-major] Brain Neoplasms / metabolism. Glioblastoma / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism
  • [MeSH-minor] Adult. Aged. Anoxia / diagnosis. Anoxia / metabolism. Anoxia / physiopathology. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Cell Hypoxia / physiology. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neovascularization, Pathologic / etiology. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / physiopathology. Predictive Value of Tests. Up-Regulation / physiology

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18621534.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit
  •  go-up   go-down


37. Chaddad Neto F, Lopes A, Alberto Filho M, Catanoce A, Joaquim AF, Oliveira Ed: Tectal glioblastoma. Arq Neuropsiquiatr; 2007 Dec;65(4A):996-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain stem gliomas are a heterogeneous group of neoplasms arising mostly in paediatric patients.
  • Tectal plate gliomas represent a particular type of brain stem tumours usually with a benign, indolent clinical course, presenting with signs of raised intracranial hypertension due to supra-tentorialhydrocephalous caused by aqueductal stenosis.
  • When a malignant tumour is clinically and radiographically suspected a biopsy should be performed to obtain histological confirmation.
  • [MeSH-major] Brain Neoplasms. Glioblastoma. Tectum Mesencephali

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094862.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


38. Hardell L, Carlberg M, Hansson Mild K: Case-control study on cellular and cordless telephones and the risk for acoustic neuroma or meningioma in patients diagnosed 2000-2003. Neuroepidemiology; 2005;25(3):120-8
MedlinePlus Health Information. consumer health - Acoustic Neuroma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed a case-control study on the use of cellular and cordless telephones and the risk for brain tumors.
  • We report the results for benign brain tumors with data from 413 cases (89% response rate), 305 with meningioma, 84 with acoustic neuroma, 24 with other types and 692 controls (84% response rate).
  • [MeSH-major] Cell Phones / utilization. Meningeal Neoplasms / etiology. Meningioma / etiology. Neuroma, Acoustic / etiology

  • Genetic Alliance. consumer health - Acoustic Neuroma.
  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 15956809.001).
  • [ISSN] 0251-5350
  • [Journal-full-title] Neuroepidemiology
  • [ISO-abbreviation] Neuroepidemiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


39. Todaro L, Christiansen S, Varela M, Campodónico P, Pallotta MG, Lastiri J, Sacerdote de Lustig E, Bal de Kier Joffé E, Puricelli L: Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors. J Neurooncol; 2007 Jun;83(2):135-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors.
  • We studied by Western blot the pattern of serum NCAM bands in patients with gliomas (n = 34), with brain metastasis of different primary cancers (n = 27) and with benign brain tumors (n = 22)] compared with healthy controls (n = 69).
  • A similar pattern was found in patients with brain metastasis or brain benign tumors, suggesting that the pattern of serum NCAM bands would be useful to detect brain tumor pathology.
  • Interestingly, we found that 9/12 patients with glioma showed a significant decrease in NCAM HMW/LMW ratio between 1-3 months after successful tumor removal.
  • Thus, serum NCAM could be a useful marker for monitoring treatment.NCAM expression was also analyzed at tissular level in 59 glioma sections from paraffined tumors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Glioma / metabolism. Neural Cell Adhesion Molecules / metabolism
  • [MeSH-minor] Adult. Aged. Brain / metabolism. Case-Control Studies. Female. Gene Expression Profiling. Humans. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Male. Melanoma / metabolism. Melanoma / secondary. Middle Aged. Protein Isoforms. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. Statistics, Nonparametric. Survival Analysis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17216340.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neural Cell Adhesion Molecules; 0 / Protein Isoforms
  •  go-up   go-down


40. Fayed N, Modrego PJ: The contribution of magnetic resonance spectroscopy and echoplanar perfusion-weighted MRI in the initial assessment of brain tumours. J Neurooncol; 2005 May;72(3):261-5
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The contribution of magnetic resonance spectroscopy and echoplanar perfusion-weighted MRI in the initial assessment of brain tumours.
  • Conventional Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) are the cornerstone in the initial evaluation of brain tumours.
  • The purpose of this study is to evaluate the contribution of Magnetic Resonance Spectroscopy (MRS) and Perfusion-weighted MRI to distinguish malignant from benign tumours.
  • We included 55 patients diagnosed with single brain tumour by CT and MRI, and final histopathological verification of the tumour type: 25 were low-grade gliomas, 8 anaplastic gliomas, 11 glioblastomas, and 11 solitary metastases.
  • We carried out brain MRS and dynamic perfusion-weighted echoplanar MRI in all cases.
  • In MRS, we found significant differences in Choline/Creatine ratios in relation to the tumour type with the highest values in high-grade gliomas and metastases.
  • We found no significant differences in the relative cerebral blood volume (rCBV) for every type of tumour.
  • The mean rCBV was 1.24 for benign tumours and 1.5 for the malignant ones(1.24 for low-grade gliomas, 1.91 for anaplastic gliomas, 1.03 for glioblastomas, and 1.57 for metastases).
  • We conclude that, individually considered, MRS is superior to Perfusion-weighted MRI in the initial assessment of brain tumours.
  • Perfusion MRI has not demonstrated predictive power to distinguish malignant from benign tumours.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Echo-Planar Imaging. Magnetic Resonance Spectroscopy
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / chemistry. Astrocytoma / diagnosis. Astrocytoma / pathology. Blood Volume / physiology. Child. Child, Preschool. Choline / metabolism. Creatine / metabolism. Creatinine / metabolism. Female. Glioma / chemistry. Glioma / diagnosis. Glioma / pathology. Humans. Lactates / metabolism. Male. Middle Aged. Neoplasm Metastasis / diagnosis. ROC Curve. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CREATINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15937650.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Lactates; AYI8EX34EU / Creatinine; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


41. Miles KA: Perfusion imaging with computed tomography: brain and beyond. Eur Radiol; 2006 Nov;16 Suppl 7:M37-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perfusion imaging with computed tomography: brain and beyond.
  • The availability of rapid imaging with multidetector CT systems and commercial analysis software has made perfusion imaging with CT an everyday technique, not only for the brain but also for other body organs.
  • Within neuroradiology, perfusion CT has attracted interest in the assessment of acute stroke but can also be used to assess secondary injury in head trauma and as an adjunct to CT angiography to evaluate cerebral spasm in subarachnoid haemorrhage.
  • Within oncology, perfusion CT provides an imaging correlate for tumour vascularity that can be used to discriminate benign and malignant lesions, as an indicator of tumour aggressiveness, to reveal occult tumour and improve the delineation of tumours during radiotherapy planning, and as a functional assessment of tumour response to therapy.
  • By exploiting the ability of CT systems to quantify contrast enhancement, CT perfusion imaging uses contrast media to assess vascular physiology and so improve diagnosis, prognosis, treatment selection and therapy monitoring.
  • [MeSH-major] Brain Neoplasms / radiography. Cerebrovascular Disorders / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18655265.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 41
  •  go-up   go-down


42. Hargrave D: Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy. Br J Neurosurg; 2009 Aug;23(4):351-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.
  • Gliomas are the most common type of paediatric brain tumour and range from benign low grade gliomas which can be resected/observed to aggressive brainstem gliomas with dismal survival rates.
  • Pilocytic astrocytoma, the most common childhood low grade brain tumour, has recently been shown to harbour an activated BRAF/MAPK/ERK pathway in the majority of cases; this represents an attractive target for new agents.
  • Brainstem glioma remains a tumour with a dismal prognosis but relatively little is known about the underlying biology and progress will require a concerted effort to collect tissue by biopsy and autopsy to allow appropriate analysis to identify and validate targets.
  • [MeSH-major] Brain Neoplasms. Glioma / pathology
  • [MeSH-minor] Adolescent. Adult. Astrocytoma / genetics. Astrocytoma / pathology. Astrocytoma / therapy. Child. Child, Preschool. Combined Modality Therapy. Drug Delivery Systems. Genetic Predisposition to Disease. Genome-Wide Association Study. Hamartoma Syndrome, Multiple / genetics. Humans. Infant. Neoplasm Staging. Neurofibromatosis 1 / genetics. Prognosis. Tuberous Sclerosis / genetics

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19637006.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 170
  •  go-up   go-down


43. Ahmed S, Burney I, Sawhney S, Al-Moundhri MS: Gastric Adenocarcinoma in Association with Tuberous Sclerosis: Case report. Sultan Qaboos Univ Med J; 2009 Apr;9(1):75-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tuberous sclerosis is an autosomal dominant disorder which presents with a constellation of signs including benign tumours in the brain and in other vital organs such as the kidneys, heart, eyes, lungs, and skin.
  • These proteins act as tumour growth suppressor agents that regulate cell proliferation and differentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Korean Med Sci. 2000 Aug;15(4):467-70 [10983700.001]
  • [Cites] Hum Genet. 2000 Oct;107(4):350-6 [11129334.001]
  • [Cites] Br J Cancer. 2001 Oct 19;85(8):1226-30 [11710839.001]
  • [Cites] J Urol. 2003 May;169(5):1635-42 [12686801.001]
  • [Cites] Chest. 1985 Sep;88(3):473-5 [4028861.001]
  • (PMID = 21509279.001).
  • [ISSN] 2075-051X
  • [Journal-full-title] Sultan Qaboos University medical journal
  • [ISO-abbreviation] Sultan Qaboos Univ Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Oman
  • [Other-IDs] NLM/ PMC3074756
  • [Keywords] NOTNLM ; Case report / Gastric cancer / Hamartoma / Lymphangiomyomatosis / Mucinous adenocarcinoma / Oman / Tuberous sclerosis
  •  go-up   go-down


44. Wang XY, Xu SJ, Li XG: Post-operative implantation metastasis of craniopharyngioma: a case report. J Int Med Res; 2010 Sep-Oct;38(5):1876-82
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Craniopharyngiomas are histologically benign epithelial tumours arising from squamous epithelial remnants of Rathke's pouch, which have a tendency to invade surrounding structures and recur after apparently complete resection.
  • They represent the most frequent non-glial tumour in children, accounting for approximately 5% of paediatric brain neoplasms.
  • [MeSH-major] Craniopharyngioma / secondary. Neoplasm Recurrence, Local / pathology. Pituitary Neoplasms / pathology

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21309505.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


45. Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S, Jegga AG, Li H, Upadhyaya M, Giovannini M, Muir D, Wallace MR, Lopez E, Serra E, Nielsen GP, Lazaro C, Stemmer-Rachamimov A, Page G, Aronow BJ, Ratner N: Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med; 2009 Jul;1(4):236-48
Guide to Pharmacology. gene/protein/disease-specific - ADGRG6 - data and references .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Understanding the biological pathways critical for common neurofibromatosis type 1 (NF1) peripheral nerve tumours is essential, as there is a lack of tumour biomarkers, prognostic factors and therapeutics.
  • We used gene expression profiling to define transcriptional changes between primary normal Schwann cells (n = 10), NF1-derived primary benign neurofibroma Schwann cells (NFSCs) (n = 22), malignant peripheral nerve sheath tumour (MPNST) cell lines (n = 13), benign neurofibromas (NF) (n = 26) and MPNST (n = 6).

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci Res. 2004 Dec 15;78(6):796-802 [15523643.001]
  • [Cites] J Neurosci. 1998 Jan 1;18(1):237-50 [9412504.001]
  • [Cites] Dev Cell. 2005 Feb;8(2):179-92 [15691760.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8633-8 [15932943.001]
  • [Cites] Nat Rev Neurosci. 2005 Sep;6(9):671-82 [16136171.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e175 [16284200.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Mar;45(3):265-76 [16283621.001]
  • [Cites] J Clin Pathol. 2006 Feb;59(2):160-5 [16443732.001]
  • [Cites] BMC Bioinformatics. 2006;7:35 [16430768.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2584-91 [16510576.001]
  • [Cites] BMC Bioinformatics. 2006;7:84 [16504070.001]
  • [Cites] Hum Mutat. 2006 Jul;27(7):716 [16786508.001]
  • [Cites] Development. 2006 Aug;133(15):2875-86 [16790476.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):593-602 [16862190.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D116-21 [17178752.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):398-407 [17202312.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4609-16 [17297459.001]
  • [Cites] Neuroscience. 2007 Jul 29;147(4):928-37 [17582688.001]
  • [Cites] Development. 2007 Sep;134(18):3271-81 [17699610.001]
  • [Cites] Genome Biol. 2007;8(9):R183 [17784955.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):105-16 [18242511.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):129-40 [18242513.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1015-24 [18281533.001]
  • [Cites] Cell Stem Cell. 2008 Jul 3;3(1):33-43 [18593557.001]
  • [Cites] Glia. 2008 Nov 1;56(14):1590-605 [18803326.001]
  • [Cites] Cell Stem Cell. 2008 Dec 4;3(6):658-69 [19041782.001]
  • [Cites] Cell Stem Cell. 2009 May 8;4(5):453-63 [19427294.001]
  • [Cites] Nucleic Acids Res. 1999 Mar 1;27(5):1359-64 [9973626.001]
  • [Cites] Hum Mol Genet. 2000 Jan 22;9(2):237-47 [10607834.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Feb;27(2):117-23 [10612798.001]
  • [Cites] Am J Epidemiol. 2000 Jan 1;151(1):33-40 [10625171.001]
  • [Cites] Mol Cell Biol. 2000 May;20(9):3198-209 [10757804.001]
  • [Cites] J Clin Invest. 2000 May;105(9):1233-41 [10791998.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):30740-5 [10900196.001]
  • [Cites] Hum Mol Genet. 2000 Dec 12;9(20):3055-64 [11115850.001]
  • [Cites] Genes Dev. 2001 Jan 1;15(1):66-78 [11156606.001]
  • [Cites] Cell. 2001 Feb 23;104(4):593-604 [11239415.001]
  • [Cites] Nat Genet. 2001 Jul;28(3):294-6 [11431704.001]
  • [Cites] Behav Brain Res. 2001 Nov 1;125(1-2):279-84 [11682119.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):41229-36 [11514554.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Aug;61(8):702-9 [12152785.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):2213-24 [12612091.001]
  • [Cites] Spine (Phila Pa 1976). 2003 Apr 15;28(8):755-63 [12698117.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] J Neurosci. 2004 Mar 10;24(10):2357-65 [15014110.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3763-71 [15173083.001]
  • [Cites] Brain Pathol. 2004 Jul;14(3):258-64 [15446580.001]
  • [Cites] J Cell Biol. 1990 Aug;111(2):645-53 [1696266.001]
  • [Cites] Glia. 1996 Aug;17(4):327-38 [8856329.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [CommentIn] EMBO Mol Med. 2009 Jul;1(4):198-200 [20049721.001]
  • (PMID = 20049725.001).
  • [ISSN] 1757-4684
  • [Journal-full-title] EMBO molecular medicine
  • [ISO-abbreviation] EMBO Mol Med
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / K01 NS049191; United States / NCI NIH HHS / CA / T32 CA059268; United States / NINDS NIH HHS / NS / K01-NS049191; United States / NCI NIH HHS / CA / T32 CA 59268
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SOX9 Transcription Factor; 0 / SOX9 protein, human
  • [Other-IDs] NLM/ PMC3378132
  •  go-up   go-down


46. Zhou GF, Wang XY, Huang MP: [BOLD-fMRI in sensory area and motor hand functional area with brain tumor in the central area]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Jul;33(7):576-81
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [BOLD-fMRI in sensory area and motor hand functional area with brain tumor in the central area].
  • OBJECTIVE: To explore the geomorphological performance, the characteristics of volume, and the largest signal intension of blood oxygenation level dependent functional magnetic resonance imaging (BOLD-fMRI) in brain tumors located in or closed to the central area.
  • METHODS: We recruited 13 normal volunteers and 31(13 benign tumors and 18 malignant tumors) patients with brain tumor located in or closed to the central area, to examine both side hand motor and tactile function by BOLD-fMRI and obtained the activation map and its superposition image with T1 imaging, the volume, and the largest signal intension of the functional area by SPM software which manipulated the raw data in the off-line work station.
  • There was difference in the activated signal pixel number and the largest signal intension of the functional area between the benign brain tumors, malignant brain tumors, and the normal volunteers (P < 0.05).
  • The shape, anatomic location, the volume, and the largest signal intension of the functional area were changed in the patients with brain tumors.
  • CONCLUSION: BOLD-fMRI is a valid method to assess the pre-surgical risk of patients with brain tumors, which can get the volume, the largest signal intension, the basic shape,and the anatomic location of the functional area.
  • [MeSH-major] Brain Neoplasms / physiopathology. Hand / physiopathology. Magnetic Resonance Imaging / methods. Motor Cortex / physiopathology. Somatosensory Cortex / physiopathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18667768.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


47. Hanemann CO: Magic but treatable? Tumours due to loss of merlin. Brain; 2008 Mar;131(Pt 3):606-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumours caused by mutations in the NF2 gene are benign and thus do not respond to classical chemotherapy.
  • The benign, and therefore genetically stable and homogenous character of the tumours allows establishment of meaningful tumour models.
  • In this review, I will first describe the phenotypes associated with 'merlin' mutations and consider differential diagnosis, in particular Schwannomatosis, for which a gene defect has been described recently.
  • [MeSH-minor] Adult. Diagnosis, Differential. Ependymoma / diagnosis. Ependymoma / genetics. Ependymoma / therapy. Humans. Meningioma / diagnosis. Meningioma / genetics. Meningioma / therapy. Middle Aged. Neurilemmoma / diagnosis. Neurilemmoma / genetics. Neurilemmoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940085.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neurofibromin 2
  • [Number-of-references] 108
  •  go-up   go-down


48. Rajesh LS, Jain D, Radotra BD, Banerjee AK, Khosla VK, Vasishta RK: Central neurocytoma: a clinico-pathological study of eight cases. Indian J Pathol Microbiol; 2006 Oct;49(4):543-5
Genetic Alliance. consumer health - Central Neurocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Central neurocytomas are benign neuronal tumours generally found in the lateral or third ventricles.
  • They are rare, comprising < 1% of all brain tumours.
  • The tumour in extraventricular location showed atypical features.
  • The present series highlights the characteristic clinical and pathological findings of this rare brain tumour.
  • Immunostaining for neuronal markers are essential for distinguishing them from other small round cell tumours of the brain.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Cerebral Ventricle Neoplasms / physiopathology. Neurocytoma / pathology. Neurocytoma / physiopathology. Neurons / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17183847.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Synaptophysin
  •  go-up   go-down


49. Payne GS, Leach MO: Applications of magnetic resonance spectroscopy in radiotherapy treatment planning. Br J Radiol; 2006 Sep;79 Spec No 1:S16-26
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While MRI and CT provide images of excellent spatial resolution, they do not always provide sufficient contrast to identify tumour extent or to identify regions of high cellular activity that might be targeted with boost doses.
  • The method is currently under evaluation, in particular in brain (where MRS has been shown to differentiate between many tumour types and grades) and in prostate (where cancer may be distinguished from normal tissue and benign prostatic hypertrophy).
  • The contrast achieved with MRS, based on tissue biochemistry, therefore provides a promising alternative for identifying tumour extent and regions of high metabolic activity.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Magnetic Resonance Spectroscopy. Patient Care Planning. Prostatic Neoplasms / radiotherapy
  • [MeSH-minor] Diagnosis, Differential. Humans. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980681.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 65
  •  go-up   go-down


50. Figarella-Branger D, Colin C, Chinot O, Nanni I, Baeza N, Fina F, Tong S, Eudes N, Quilichini B, Romain S, Metellus P, Fuentes S, Barrié M, Boucard C, Fraslon C, Bonavita MJ, Martin PM, Ouafik L: [AP-HM tumour tissue bank: molecular signature of gliomas]. Med Sci (Paris); 2006 Jan;22 Spec No 1:54-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [AP-HM tumour tissue bank: molecular signature of gliomas].
  • [Transliterated title] Tumorothèque de l'AP-HM: cartographie moléculaire des gliomes.
  • The AP-HM tissue bank is the largest one in France regarding some collections, including brain tumors.
  • In particular because some benign gliomas such as pilocytic astrocytomas (WHO grade I) can be misclassified as malignant ones such as glioblastomas (grade IV) the first aim of our study was to find accurate diagnostic markers.
  • [MeSH-major] Brain Neoplasms / genetics. Glioma / genetics. Tissue Banks

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16705945.001).
  • [ISSN] 0767-0974
  • [Journal-full-title] Médecine sciences : M/S
  • [ISO-abbreviation] Med Sci (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] France
  • [Number-of-references] 18
  •  go-up   go-down


51. Sasikala M, Kumaravel N: A wavelet-based optimal texture feature set for classification of brain tumours. J Med Eng Technol; 2008 May-Jun;32(3):198-205
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A wavelet-based optimal texture feature set for classification of brain tumours.
  • In this work, the classification of brain tumours in magnetic resonance images is studied by using optimal texture features.
  • These features are used to classify three sets of brain images - normal brain, benign tumour and malignant tumour.
  • Each selected brain region of interest is characterized with both its energy and texture features extracted from the selected high frequency subband.
  • [MeSH-major] Algorithms. Artificial Intelligence. Brain Neoplasms / diagnosis. Image Interpretation, Computer-Assisted / methods. Magnetic Resonance Imaging / methods. Pattern Recognition, Automated / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18432467.001).
  • [ISSN] 0309-1902
  • [Journal-full-title] Journal of medical engineering & technology
  • [ISO-abbreviation] J Med Eng Technol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


52. Kubo O, Chernov M, Izawa M, Hayashi M, Muragaki Y, Maruyama T, Hori T, Takakura K: Malignant progression of benign brain tumors after gamma knife radiosurgery: is it really caused by irradiation? Minim Invasive Neurosurg; 2005 Dec;48(6):334-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant progression of benign brain tumors after gamma knife radiosurgery: is it really caused by irradiation?
  • Malignant transformation of benign neoplasm after radiosurgery is usually diagnosed based on the initial presence of benign tumor, its exposure to ionizing radiation, elapsed time from radiation exposure to malignant progression, and different histological characteristics or growth rate of the regrowing tumor comparing with those originally treated.
  • Three presented cases fulfilled these diagnostic criteria; however, it seems that progression of the tumors (schwannoma, meningioma, chordoma) resulted from the natural course of the disease, rather than represented side effects of gamma knife radiosurgery.
  • Evaluation of the proliferative potential of the benign neoplasm before radiosurgical treatment either directly, if tumor sampling is available, or indirectly, by calculation of the tumor growth rate and/or analysis of the data of the metabolic imaging (PET, MRS) is important for identification of "aggressive" subtypes, precise prediction of prognosis, and confirmation of the radiation-induced malignant transformation in cases of tumor regrowth.
  • [MeSH-major] Brain Neoplasms / surgery. Cell Transformation, Neoplastic / radiation effects. Chordoma / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasms, Radiation-Induced / physiopathology. Neurilemmoma / surgery. Radiosurgery / adverse effects
  • [MeSH-minor] Adult. Brain Diseases / surgery. Cell Proliferation. Female. Humans. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16432782.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


53. Happle C, Wetzke M, Hermann EJ, Krauss JK, Hartmann H, Lücke T: ['Cases against KiSS': a diagnostic algorithm for children with torticollis]. Klin Padiatr; 2009 Dec;221(7):430-5
MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present two infants with brain tumours who developed torticollis and further neurological findings such as ataxia and reflex differences.
  • In both cases, symptoms caused by the tumour were interpreted as "KiSS-syndrome", and appropriate diagnostics and therapy were delayed for months.
  • Whereas most cases are benign, there is a long list of serious differential diagnoses for torticollis in infants.
  • [MeSH-major] Algorithms. Astrocytoma / diagnosis. Cerebellar Neoplasms / diagnosis. Cervical Vertebrae. Ganglioglioma / diagnosis. Magnetic Resonance Imaging. Neoplasms, Second Primary / diagnosis. Spinal Diseases / diagnosis. Torticollis / etiology
  • [MeSH-minor] Child, Preschool. Diagnostic Errors. Gait Disorders, Neurologic / etiology. Humans. Infant. Male. Microsurgery. Neoplasm, Residual / diagnosis. Neurologic Examination. Postoperative Complications / diagnosis. Reoperation. Syndrome

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Georg Thieme Verlag KG Stuttgart New York.
  • (PMID = 20013566.001).
  • [ISSN] 1439-3824
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


54. Zakrzewski K, Biernat W, Liberski PP, Polis L, Nowoslawska E: Pilocytic astrocytoma as a predominant component of a recurrent complex type DNT. Folia Neuropathol; 2009;47(3):284-8
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dysembryoplastic neuroepithelial tumour (DNT) is a benign lesion of the cerebral hemispheres usually presenting minimal biological activity after surgical excision.
  • We report an unusual case of a 7-year-old girl with a temporal lobe DNT, which recurred four years after subtotal resection of the tumour.
  • In the recurrent lesion we identified pilocytic astrocytoma (PA) as a predominant component of the tumour.
  • Clinical presentation of the primary tumour consisted of partial simple seizures, while the recurrent tumour manifested with headache and vomiting.
  • We conclude that patients with incompletely removed DNT may suffer local recurrence of that tumour.
  • In rare cases development of a secondary, histologically different neoplasm may also occur.

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19813149.001).
  • [ISSN] 1641-4640
  • [Journal-full-title] Folia neuropathologica
  • [ISO-abbreviation] Folia Neuropathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


55. Rozmovits L, Khu KJ, Osman S, Gentili F, Guha A, Bernstein M: Information gaps for patients requiring craniotomy for benign brain lesion: a qualitative study. J Neurooncol; 2010 Jan;96(2):241-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Information gaps for patients requiring craniotomy for benign brain lesion: a qualitative study.
  • Twenty-five semi-structured interviews were conducted with ambulatory adult patients who had undergone surgery for a benign brain tumor, arteriovenous malformation, or unruptured aneurysm.

  • MedlinePlus Health Information. consumer health - Choosing a Doctor or Health Care Service.
  • MedlinePlus Health Information. consumer health - Talking With Your Doctor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] ANZ J Surg. 2001 Jan;71(1):24-6 [11167593.001]
  • [Cites] Heart. 2001 Dec;86(6):626-31 [11711453.001]
  • [Cites] BMJ. 2003 Nov 15;327(7424):1159-61 [14615345.001]
  • [Cites] Br Heart J. 1984 Oct;52(4):468-70 [6477788.001]
  • [Cites] J R Soc Med. 1994 Mar;87(3):149-52 [8158593.001]
  • [Cites] Neurosurgery. 2009 Jan;64(1):40-7; discussion 47 [19145155.001]
  • [Cites] Eur J Cardiothorac Surg. 2005 Sep;28(3):407-14 [16055340.001]
  • [Cites] Mayo Clin Proc. 2006 Mar;81(3):307-12 [16529133.001]
  • [Cites] J Med Ethics. 2006 Oct;32(10):612-6 [17012508.001]
  • [Cites] Int J Qual Health Care. 2007 Apr;19(2):113-9 [17277008.001]
  • [Cites] N Z Med J. 1998 Sep 11;111(1073):340-2 [9785548.001]
  • (PMID = 19575147.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] Canada / Canadian Institutes of Health Research / / MOP 77670
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2808535
  •  go-up   go-down


56. Ng WH, Lim T, Yeo TT: Pleomorphic xanthoastrocytoma in elderly patients may portend a poor prognosis. J Clin Neurosci; 2008 Apr;15(4):476-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic xanthoastrocytoma (PXA) is a rare primary astrocytic tumour of the nervous system usually involving the superficial temporal cortex of children and young adults.
  • Although the tumour may exhibit histological features of pleomorphism or cellular atypia, the overall prognosis is good compared with other glial tumours, with only 30% of PXA recurring and 20% undergoing anaplastic transformation.
  • Increased mitotic activity, high MIB-1 and proliferating cell nuclear antigen labelling indices and necrosis are poor prognostic factors, whereas abundant lymphocytic infiltration is associated with more benign biological behaviour.
  • Although a rare and benign tumour type, PXA in the elderly tend to be more malignant, may have the radiological appearance of a malignant tumour and have poor prognosis.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis
  • [MeSH-minor] Aged. Female. Glioblastoma / diagnosis. Humans. Ki-67 Antigen / metabolism. Magnetic Resonance Imaging. Prognosis. Temporal Lobe / pathology

  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18255294.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


57. Knisely JP, Linskey ME: Less common indications for stereotactic radiosurgery or fractionated radiotherapy for patients with benign brain tumors. Neurosurg Clin N Am; 2006 Apr;17(2):149-67, vii
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Less common indications for stereotactic radiosurgery or fractionated radiotherapy for patients with benign brain tumors.
  • Microsurgical resection remains the mainstay of treatment for truly benign brain tumors that can be safely resected because of the potential for permanent cure with most histologic findings, including most of the histologic findings discussed in this article.
  • Physicians must keep in mind the indolent nature of many of the benign brain tumors and realize that many patients are likely to live out normal life spans if tumor control is achieved.
  • Therefore, it is not sufficient simply to consider local tumor control rates and short-term toxicity risks when choosing between surgery, stereotactic radiosurgery, and fractionated radiotherapy.
  • For benign brain tumors, these decisions may have consequences that last for decades.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Patient Selection
  • [MeSH-minor] Astrocytoma / diagnosis. Astrocytoma / radiotherapy. Astrocytoma / surgery. Chordoma / diagnosis. Chordoma / radiotherapy. Chordoma / surgery. Dose Fractionation. Glomus Tumor / diagnosis. Glomus Tumor / radiotherapy. Glomus Tumor / surgery. Humans. Magnetic Resonance Imaging. Neurocytoma / diagnosis. Neurocytoma / radiotherapy. Neurocytoma / surgery. Paraganglioma / diagnosis. Paraganglioma / radiotherapy. Paraganglioma / surgery. Paraganglioma, Extra-Adrenal / diagnosis. Paraganglioma, Extra-Adrenal / radiotherapy. Paraganglioma, Extra-Adrenal / surgery. Pinealoma / diagnosis. Pinealoma / radiotherapy. Pinealoma / surgery. Radiosurgery / methods. Skull Base Neoplasms / diagnosis. Skull Base Neoplasms / radiotherapy. Skull Base Neoplasms / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793507.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 148
  •  go-up   go-down


58. De Wever W, Bruyeer E, Demaerel P, Wilms G, Coolen J, Verschakelen J: Staging of lung cancer. Do we need a diagnostic CT of the brain after an integrated PET/CT for the detection of brain metastases? JBR-BTR; 2010 Mar-Apr;93(2):71-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging of lung cancer. Do we need a diagnostic CT of the brain after an integrated PET/CT for the detection of brain metastases?
  • Brain CT has been recommended in staging of patients with lung cancer because of its usefulness in the detection of metastases.
  • Purpose of this study is to examine if a diagnostic brain CT (CT,) can be obviated when an integrated PET/CT (PET/CT) is available.
  • 87 consecutive patients underwent a diagnostic brain CT and a whole-body PET/CT within a period of 3 weeks to stage a known primary tumour.
  • CT examinations were evaluated by two experienced neuroradiologists on the detection of brain lesions (benign and malignant).
  • Considering the CT, as standard of reference, sensitivity, specificity, PPV, NPV and accuracy for the brain CT of PET/CT (CT2) and PET/CT were respectively 83%, 96%, 77%, 97%, 94% and 69%, 98%, 90%, 95%, 94%.
  • Considering the clinical diagnosis as standard of reference these figures were for CT1, CT2 and PET/CT respectively 80%, 100%, 100%, 96%, 96% and 66%, 95%, 77%, 93%, 90% and 66%, 97%, 83%, 93%, 91%.
  • The comparison of the additional CT in PET/CT with a diagnostic CT of the brain did not yield a statistical difference in the detection of brain lesions despite the inferior quality of the CT component of PET/CT.
  • A diagnostic brain CT can be obviated when a PET/CT is available.
  • [MeSH-major] Brain Neoplasms / radiography. Brain Neoplasms / secondary. Lung Neoplasms / pathology. Lung Neoplasms / radiography. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Brain / radiography. Contrast Media. Female. Humans. Male. Middle Aged. Neoplasm Staging. Observer Variation. Radiographic Image Enhancement / methods. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity. Whole Body Imaging / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20524514.001).
  • [ISSN] 0302-7430
  • [Journal-full-title] JBR-BTR : organe de la Société royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)
  • [ISO-abbreviation] JBR-BTR
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


59. Jagannathan J, Kanter AS, Sheehan JP, Jane JA Jr, Laws ER Jr: Benign brain tumors: sellar/parasellar tumors. Neurol Clin; 2007 Nov;25(4):1231-49, xi
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign brain tumors: sellar/parasellar tumors.
  • Neoplasms of the sellar region include pituitary adenomas, craniopharyngiomas, Rathke's cleft cysts, and, less commonly, meningiomas, germinomas, and hamartomas.
  • The diagnosis of sellar lesions involves a multidisciplinary effort; detailed endocrinologic, ophthalmologic, and neurologic tests are critical.
  • The management of pituitary tumors varies.
  • For most tumors, transsphenoidal resection remains the mainstay of treatment.
  • [MeSH-major] Brain Neoplasms / pathology. Pituitary Neoplasms / pathology. Sella Turcica / pathology
  • [MeSH-minor] Acromegaly / diagnosis. Chemotherapy, Adjuvant. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Pituitary ACTH Hypersecretion / diagnosis. Pituitary ACTH Hypersecretion / etiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964033.001).
  • [ISSN] 0733-8619
  • [Journal-full-title] Neurologic clinics
  • [ISO-abbreviation] Neurol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 69
  •  go-up   go-down


60. Cozzi L, Clivio A, Vanetti E, Nicolini G, Fogliata A: Comparative planning study for proton radiotherapy of benign brain tumors. Strahlenther Onkol; 2006 Jul;182(7):376-81
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative planning study for proton radiotherapy of benign brain tumors.
  • Twelve cases of "benign" brain tumors were considered (meningiomas, neurinomas, and hypophyseal adenomas).
  • Organs at risk included chiasm, brainstem, eyes and optic nerves as well as the not otherwise specified healthy brain tissue in view of long-term toxicity.
  • Plans designed with the spot-scanning technique presented the minimum involvement of healthy tissue (e. g., the lowest maximum significant dose to healthy brain [25.6 Gy] or the lowest conformity index [CI(95) = 1.3], between 38% and 46% lower than for the other techniques).
  • [MeSH-major] Brain Neoplasms / radiotherapy. Protons / therapeutic use. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Computer-Assisted / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16826355.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


61. Prabhu SS, Bruner JM: Large oculomotor schwannoma presenting as a parasellar mass: A case report and literature review. Surg Neurol Int; 2010;1:15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The common site of tumor occurrence in this nerve is the segment within the interpeduncular cistern and the cavernous sinus.
  • The radiological features of the mass were more consistent with a medial sphenoid wing meningioma causing brain stem compression.
  • Complete resection of the tumor was achieved via a left pterional approach.
  • CONCLUSION: The management of these large benign tumors with brain stem compression includes surgical resection.
  • Intraoperative anatomical preservation of the third nerve was impossible given its course in the tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1992 Sep;38(3):216-24 [1440207.001]
  • [Cites] Neurochirurgie. 1992;38(3):183-7 [1461338.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Feb;30(2):132-6 [1695335.001]
  • [Cites] Clin Neurol Neurosurg. 1990;92(4):333-5 [1963824.001]
  • [Cites] Br J Neurosurg. 1990;4(1):69-72 [2185790.001]
  • [Cites] Surg Neurol. 1985 Sep;24(3):275-8 [4023908.001]
  • [Cites] Surg Neurol. 2007 Jan;67(1):83-8; discussion 88 [17210311.001]
  • [Cites] J Neurosurg. 1982 Jun;56(6):854-6 [7077388.001]
  • [Cites] J Neurosurg. 1982 Oct;57(4):563-5 [7108608.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(11):1147-51 [9870060.001]
  • [Cites] Br J Neurosurg. 2003 Apr;17(2):168-73 [12820761.001]
  • [Cites] Skull Base Surg. 1994;4(4):219-26 [17171175.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1981 May;44(5):397-401 [7021770.001]
  • (PMID = 20657696.001).
  • [ISSN] 2152-7806
  • [Journal-full-title] Surgical neurology international
  • [ISO-abbreviation] Surg Neurol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2908360
  • [Keywords] NOTNLM ; Meningioma / oculomotor schwannoma / skull base
  •  go-up   go-down


62. Braun M, Finke C, Ostendorf F, Lehmann TN, Hoffmann KT, Ploner CJ: Reorganization of associative memory in humans with long-standing hippocampal damage. Brain; 2008 Oct;131(Pt 10):2742-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We tested this hypothesis by investigating visuo-spatial associative memory in two patient groups with similar surgical lesions to the right medial temporal lobe, but different preoperative disease courses (benign brain tumours, mean: 1.8 +/- 0.6 years, n = 5, age: 28.2 +/- 4.0 years; hippocampal sclerosis, mean: 16.8 +/- 1.9 years, n = 9, age: 38.9 +/- 4.1 years).
  • Compared to controls (n = 14), tumour patients showed a significant delay-dependent deficit in memory of colour-location associations.
  • No such deficit was observed in hippocampal sclerosis patients, which appeared to benefit from a compensatory mechanism that was inefficient in tumour patients.
  • These results indicate that long-standing hippocampal damage can yield significant functional reorganization of the neural substrate underlying memory in the human brain.
  • [MeSH-minor] Adult. Association Learning. Brain Neoplasms / pathology. Brain Neoplasms / psychology. Case-Control Studies. Color Perception. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neuronal Plasticity. Neuropsychological Tests. Statistics, Nonparametric. Temporal Lobe / pathology. Time Factors

  • MedlinePlus Health Information. consumer health - Memory.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18757465.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


63. Rosenberg DS, Demarquay G, Jouvet A, Le Bars D, Streichenberger N, Sindou M, Kopp N, Mauguière F, Ryvlin P: [11C]-Methionine PET: dysembryoplastic neuroepithelial tumours compared with other epileptogenic brain neoplasms. J Neurol Neurosurg Psychiatry; 2005 Dec;76(12):1686-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [11C]-Methionine PET: dysembryoplastic neuroepithelial tumours compared with other epileptogenic brain neoplasms.
  • BACKGROUND AND OBJECTIVES: Brain tumours responsible for longstanding partial epilepsy are characterised by a high prevalence of dysembryoplastic neuroepithelial tumour (DNT), whose natural evolution is much more benign than that of gliomas.
  • The preoperative diagnosis of DNT, which is not yet feasible on the basis of available clinical and imaging data, would help optimise the therapeutic strategy for this type of tumour.
  • This study tested whether [(11)C]-methionine positron emission tomography (MET-PET) could help to distinguish DNTs from other epileptogenic brain tumours.
  • METHODS: Prospective study of 27 patients with partial epilepsy of at least six months duration related to a non-rapidly progressing brain tumour on magnetic resonance imaging (MRI).
  • A structured visual analysis, which distinguished between normal, moderately abnormal, or markedly abnormal tumour methionine uptake, as well as various regions of interest and semiquantitative measurements were conducted.
  • MET-PET visual findings significantly differed between the various tumour types (p<0.0002), regardless of gadolinium enhancement on MRI, and were confirmed by semiquantitative analysis (p<0.001 for all calculated ratios).
  • All gliomas and gangliogliomas were associated with moderately or markedly increased tumour methionine uptake, whereas 7/11 DNTs had a normal methionine uptake, including all six located in the mesiotemporal structures.
  • CONCLUSION: Normal MET-PET findings in patient with an epileptogenic and non-rapidly progressing brain tumour are suggestive of DNT, whereas a markedly increased tumour methionine uptake makes this diagnosis unlikely.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Epilepsy / etiology. Glioma / radionuclide imaging. Neoplasms, Neuroepithelial / radionuclide imaging. Teratoma / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain. 1994 Jun;117 ( Pt 3):461-75 [8032857.001]
  • [Cites] Ann Diagn Pathol. 2003 Aug;7(4):240-4 [12913847.001]
  • [Cites] Acta Neuropathol. 1994;88(2):166-73 [7985497.001]
  • [Cites] J Neurooncol. 1994;22(3):275-9 [7760107.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jul;54(4):513-20 [7541447.001]
  • [Cites] J Neurol Sci. 1995 Sep;132(1):20-7 [8523026.001]
  • [Cites] Ann Pathol. 1996;16(3):174-81 [8766174.001]
  • [Cites] Clin Neuropathol. 1996 Jan-Feb;15(1):47-53 [8998857.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Feb;17(2):345-53 [8938309.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):276-87; discussion 287-8 [9007859.001]
  • [Cites] J Nucl Med. 1997 Apr;38(4):517-22 [9098193.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):79-84 [9210054.001]
  • [Cites] J Neurooncol. 1998 Feb;36(3):279-83 [9524106.001]
  • [Cites] Neurosurg Rev. 1998;21(1):31-5 [9584283.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1038-43 [9588548.001]
  • [Cites] J Nucl Med. 1998 May;39(5):778-85 [9591574.001]
  • [Cites] Neurology. 1998 May;50(5):1316-22 [9595980.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 May;19(5):801-6 [9613489.001]
  • [Cites] AJR Am J Roentgenol. 1999 Apr;172(4):1103-7 [10587156.001]
  • [Cites] Neurosurg Rev. 1999 Dec;22(4):210-4 [10682929.001]
  • [Cites] J Neurosurg. 2000 Apr;92(4):722-5 [10761668.001]
  • [Cites] Epilepsia. 2004 Jan;45(1):41-5 [14692906.001]
  • [Cites] Neurology. 1982 Dec;32(12):1323-9 [6983044.001]
  • [Cites] J Comput Assist Tomogr. 1985 Jul-Aug;9(4):683-9 [3926834.001]
  • [Cites] AJNR Am J Neuroradiol. 1985 Jul-Aug;6(4):505-14 [2992257.001]
  • [Cites] J Neurooncol. 1986;3(4):397-404 [3485705.001]
  • [Cites] J Comput Assist Tomogr. 1987 Mar-Apr;11(2):208-13 [3493274.001]
  • [Cites] Invest Radiol. 1987 May;22(5):360-71 [3496318.001]
  • [Cites] J Nucl Med. 1988 Mar;29(3):421-3 [3258029.001]
  • [Cites] Neurosurgery. 1988 Nov;23(5):545-56 [3143922.001]
  • [Cites] Neurosurgery. 1989 Nov;25(5):720-8 [2586726.001]
  • [Cites] J Nucl Med. 1991 Apr;32(4):616-22 [2013802.001]
  • [Cites] J Nucl Med. 1991 Apr;32(4):726-8 [2013813.001]
  • [Cites] J Neurooncol. 1991 Feb;10(1):85-91 [2022975.001]
  • [Cites] Radiology. 1993 Jan;186(1):45-53 [8380108.001]
  • [Cites] J Nucl Med. 1993 Nov;34(11):1936-43 [8229238.001]
  • [Cites] J Neurosurg. 1993 Dec;79(6):859-66 [8246054.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):283-95 [8293188.001]
  • [Cites] Brain Pathol. 1993 Oct;3(4):371-80 [8293193.001]
  • [Cites] Acta Neuropathol. 1993;86(5):433-8 [8310793.001]
  • [Cites] Histopathology. 1999 Apr;34(4):342-56 [10231402.001]
  • [Cites] J Child Neurol. 1999 Oct;14(10):673-7 [10511341.001]
  • [Cites] J Nucl Med. 2000 Jul;41(7):1250-5 [10914918.001]
  • [Cites] Eur J Nucl Med. 2000 Jul;27(7):778-87 [10952489.001]
  • [Cites] Clin Nucl Med. 2000 Sep;25(9):694-7 [10983756.001]
  • [Cites] Ann Pathol. 2000 Oct;20(5):429-37 [11084410.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):746-50 [11702862.001]
  • [Cites] J Neuroradiol. 2001 Dec;28(4):230-40 [11924137.001]
  • [Cites] Epileptic Disord. 2002 Jun;4(2):99-119 [12105073.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):868-73 [12692687.001]
  • [Cites] Neurosurgery. 1994 May;34(5):815-23; discussion 823-4 [8052378.001]
  • (PMID = 16291894.001).
  • [ISSN] 0022-3050
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatr.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; AE28F7PNPL / Methionine
  • [Other-IDs] NLM/ PMC1739454
  •  go-up   go-down


64. van Muiswinkel KW, Meuzelaar JJ: [Papillary fibroelastoma: a rare cause of brain embolism]. Ned Tijdschr Geneeskd; 2008 Jul 5;152(27):1532-6
Genetic Alliance. consumer health - Embolism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Papillary fibroelastoma: a rare cause of brain embolism].
  • [Transliterated title] Het papillair fibro-elastoom van het hart als zeldzame oorzaak van een hersenembolie.
  • Neurological examination raised the suspicion of cerebral ischaemia due to an embolism.
  • One patient had a stalked tumour of the mitral valve and the other had a spherical tumour of the aortic valve which was clearly seen on ultrasound examination, both tumours presumably a papillary fibroelastoma.
  • Pathological examination confirmed the diagnosis of papillary fibroelastoma in both patients.
  • Papillary fibroelastoma is a rare benign primary cardiac tumour that is usually noticed when it has caused cerebrovascular ischaemia.
  • Surgical excision of the tumour is the treatment of choice.
  • [MeSH-major] Fibroma / complications. Heart Neoplasms / complications. Intracranial Embolism / etiology. Papillary Muscles / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18681364.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


65. Kalthur G, Kumar P, Devi U, Ali S, Upadhya R, Pillai S, Rao A: Susceptibility of peripheral lymphocytes of brain tumour patients to in vitro radiation-induced DNA damage, a preliminary study. Clin Exp Med; 2008 Sep;8(3):147-50
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Susceptibility of peripheral lymphocytes of brain tumour patients to in vitro radiation-induced DNA damage, a preliminary study.
  • OBJECTIVE: The present investigation aimed to study the susceptibility of lymphocytes collected from brain tumour patients to radiation-induced DNA damage under in vitro conditions.
  • METHODS: The peripheral lymphocytes collected from brain tumour patients were exposed to 2-Gy gamma radiation.
  • RESULTS: Lymphocytes of patients with benign and malignant tumour had a significantly higher (p < 0.001) baseline DNA damage compared to lymphocytes from normal subjects.
  • A significant increase (p < 0.001) in DNA damage was observed immediately after irradiation of lymphocytes from healthy subjects and brain tumour patients.
  • DISCUSSION: In conclusion, the lymphocytes of brain tumour patients possess a higher level of basal DNA damage and exhibit a higher susceptibility to a clastogenic agent like radiation.
  • [MeSH-major] Brain Neoplasms / blood. DNA Damage. Lymphocytes / radiation effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18791687.001).
  • [ISSN] 1591-8890
  • [Journal-full-title] Clinical and experimental medicine
  • [ISO-abbreviation] Clin. Exp. Med.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


66. Hohenstein C, Herdtle S: Unexpected death from a colloid cyst. Int J Emerg Med; 2010;3(1):65-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Colloid cysts are usually benign brain tumors, which rarely cause acute neurological deterioration with sudden death due to an acute increase of intracranial pressure.
  • CONCLUSION: Subtle distinctions between symptoms due to intracranial hypertension, which typically cause headache and vomiting, and true gastroenteritis are discussed as well as the pathophysiology of neurogenic pulmonary edema and the origin of cerebral-triggered cardiac dysrhythmias.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1996 Feb;38(2):392-5 [8869070.001]
  • [Cites] Ann Emerg Med. 1997 Apr;29(4):524-8 [9095015.001]
  • [Cites] Clin Neurol Neurosurg. 2002 Sep;104(4):367-70 [12140107.001]
  • [Cites] Childs Nerv Syst. 2006 Mar;22(3):305-9 [16180045.001]
  • [Cites] J Clin Neurosci. 1995 Oct;2(4):307-11 [18638833.001]
  • [Cites] Acta Anaesthesiol Scand. 2007 Apr;51(4):447-55 [17378783.001]
  • [Cites] Physiol Res. 2008;57(4):499-506 [18052674.001]
  • [Cites] Am J Forensic Med Pathol. 2008 Jun;29(2):170-2 [18520488.001]
  • [Cites] Pediatr Cardiol. 2006 Mar-Apr;27(2):286-8 [16463127.001]
  • (PMID = 20414387.001).
  • [ISSN] 1865-1380
  • [Journal-full-title] International journal of emergency medicine
  • [ISO-abbreviation] Int J Emerg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2850975
  • [Keywords] NOTNLM ; Cardiopulmonary complication / Colloid cyst / Unexpected death
  •  go-up   go-down


67. Liu J, Zheng S, Yu JK, Yu XB, Liu WG, Zhang JM, Hu X: [Establishment of diagnostic model of cerebrospinal protein fingerprint pattern for glioma and its clinical application]. Zhejiang Da Xue Xue Bao Yi Xue Ban; 2005 Mar;34(2):141-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Seventy-five samples of cerebrospinal fluid from patients with gliomas, benign brain tumors and mild brain traumas were collected.
  • A total of 50 samples from gliomas and non-brain-tumors were divided into training sets (33 cases including 17 gliomas and 16 non-brain-tumors) and testing sets (17 cases including 5 gliomas and 12 non-brain-tumors).
  • The cerebrospinal proteins bound to H4 chip were detected by SELDI-TOF MS, the profiles of cerebrospinal protein were gained and then analyzed with artificial neural network algorithm (ANN); and the diagnostic model of cerebrospinal protein profiles for differentiating gliomas from non-brain-tumors was established.
  • Forty-seven of cerebrospinal samples of gliomas and benign brain tumors were divided into training sets (31 cases including 13 gliomas and 18 benign brain tumors) and testing sets (16 cases including 9 gliomas and 7 benign brain tumors), the diagnostic model of cerebrospinal protein profiles for differentiating gliomas from benign brain tumors was established based on the same method.
  • RESULT: The diagnostic model of cerebrospinal protein profiles for differentiating gliomas from non-brain-tumors was established and was challenged with the test set randomly, the sensitivity and specificity were 100% and 91.7%, respectively.
  • The cerebrospinal protein profiling model for differentiating gliomas from benign brain tumors was also developed and was challenged with the test set randomly, the sensitivity and specificity were 88.9%, and 100%, respectively.
  • CONCLUSION: The technology of SELDI-TOF MS which combined with analysis tools of bioinformatics is a novel effective method for screening and identifying tumor biomarkers of gliomas and it may provide a new approach for the clinical diagnosis of glioma.
  • [MeSH-major] Brain Neoplasms / cerebrospinal fluid. Cerebrospinal Fluid Proteins / genetics. Glioma / cerebrospinal fluid. Peptide Mapping / standards
  • [MeSH-minor] Adult. Aged. Algorithms. Biomarkers, Tumor. Diagnosis, Differential. Female. Humans. Male. Meningioma / cerebrospinal fluid. Meningioma / diagnosis. Middle Aged. Neural Networks (Computer). Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15812888.001).
  • [ISSN] 1008-9292
  • [Journal-full-title] Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
  • [ISO-abbreviation] Zhejiang Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cerebrospinal Fluid Proteins
  •  go-up   go-down


68. Jesneck JL, Mukherjee S, Yurkovetsky Z, Clyde M, Marks JR, Lokshin AE, Lo JY: Do serum biomarkers really measure breast cancer? BMC Cancer; 2009 May 28;9:164
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The classifiers distinguished normal tissue from benign lesions similarly at AUC = 0.80 +/- 0.05.
  • However, the serum proteins of benign and malignant lesions were indistinguishable (AUC = 0.55 +/- 0.06).
  • The classification tasks of normal vs. cancer and normal vs. benign selected the same top feature: MIF, which suggests that the biomarkers indicated inflammatory response rather than cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Biomark. 2006;2(6):235-48 [17264395.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):334-41 [17301268.001]
  • [Cites] Ann Surg Oncol. 2007 Sep;14(9):2470-6 [17594124.001]
  • [Cites] Med Decis Making. 2000 Jul-Sep;20(3):323-31 [10929855.001]
  • [Cites] Med Phys. 2000 Jul;27(7):1509-22 [10947254.001]
  • [Cites] Semin Oncol. 2001 Feb;28(1):53-67 [11254867.001]
  • [Cites] Proteomics. 2001 Oct;1(10):1205-15 [11721633.001]
  • [Cites] Science. 2002 Jun 28;296(5577):2391-4 [12089442.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1194-7 [12142372.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6740-9 [12438275.001]
  • [Cites] Expert Opin Ther Targets. 2003 Apr;7(2):153-64 [12667094.001]
  • [Cites] Proteomics. 2003 Apr;3(4):433-9 [12687611.001]
  • [Cites] J Neurochem. 2003 Jul;86(2):519-28 [12871593.001]
  • [Cites] Bioinformatics. 2003 Aug 12;19(12):1484-91 [12912828.001]
  • [Cites] Thyroid. 2003 Jun;13(6):547-51 [12930598.001]
  • [Cites] Radiology. 2003 Oct;229(1):3-8 [14519861.001]
  • [Cites] Med Phys. 2004 Jan;31(1):81-90 [14761024.001]
  • [Cites] Clin Chem. 2004 Mar;50(3):559-63 [14726467.001]
  • [Cites] Cancer. 2004 Oct 15;101(8):1767-75 [15386335.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5B):3221-4 [15510614.001]
  • [Cites] Proc Natl Acad Sci U S A. 1976 Dec;73(12):4329-33 [188033.001]
  • [Cites] Radiology. 1984 Feb;150(2):335-7 [6691085.001]
  • [Cites] Radiology. 1987 Jan;162(1 Pt 1):167-70 [3024209.001]
  • [Cites] Invest Radiol. 1988 Oct;23(10):729-33 [3056868.001]
  • [Cites] Blood. 1989 May 1;73(6):1504-12 [2653458.001]
  • [Cites] Breast Cancer Res Treat. 1989 Mar;13(2):123-33 [2730960.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):193-9 [2295042.001]
  • [Cites] Endocrinol Jpn. 1989 Dec;36(6):873-9 [2483831.001]
  • [Cites] Immunol Today. 1993 Oct;14(10):506-12 [7506035.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Mar;80(3):922-6 [7883851.001]
  • [Cites] J Clin Invest. 1995 Mar;95(3):1370-6 [7883984.001]
  • [Cites] J Exp Med. 1996 Jan 1;183(1):147-57 [8551218.001]
  • [Cites] Am J Prev Med. 1996 Sep-Oct;12(5):340-1 [8909643.001]
  • [Cites] FASEB J. 1996 Dec;10(14):1607-13 [9002552.001]
  • [Cites] Clin Biochem. 1997 Feb;30(1):53-6 [9056110.001]
  • [Cites] Infect Immun. 1997 Nov;65(11):4734-7 [9353058.001]
  • [Cites] Cell. 1998 May 1;93(3):411-22 [9590175.001]
  • [Cites] Biochimie. 1998 Aug-Sep;80(8-9):673-87 [9865490.001]
  • [Cites] J Urol. 1999 Aug;162(2):293-306 [10411025.001]
  • [Cites] Science. 1999 Jul 30;285(5428):727-9 [10426993.001]
  • [Cites] Oncology. 2004;67(5-6):359-67 [15713991.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7 [15824174.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):529-34 [15863156.001]
  • [Cites] J Thromb Haemost. 2008 Sep;6(9):1586-94 [18541003.001]
  • [Cites] Cancer Control. 2007 Oct;14(4):360-8 [17914336.001]
  • [Cites] Pathol Oncol Res. 2007;13(4):360-4 [18158573.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1508-17 [18257519.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1419-26 [18303830.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1395-402 [18303834.001]
  • [Cites] Cancer Biomark. 2008;4(2):73-81 [18503158.001]
  • [Cites] Am J Obstet Gynecol. 2008 Sep;199(3):215-23 [18468571.001]
  • [Cites] J Proteome Res. 2009 Jan;8(1):362-73 [19053527.001]
  • [Cites] Cancer Treat Rev. 2000 Apr;26(2):91-102 [10772967.001]
  • [Cites] Bioinformatics. 2005 May 15;21(10):2394-402 [15713736.001]
  • [Cites] Intern Med J. 2005 Jul;35(7):419-26 [15958113.001]
  • [Cites] Tumour Biol. 2005 Nov-Dec;26(6):281-93 [16254457.001]
  • [Cites] Clin Chem. 2006 Mar;52(3):345-51 [16410341.001]
  • [Cites] Breast Cancer Res Treat. 2006 Mar;96(1):83-90 [16322896.001]
  • [Cites] Hell J Nucl Med. 2006 Jan-Apr;9(1):60-4 [16617400.001]
  • [Cites] BMC Bioinformatics. 2006;7:197 [16606446.001]
  • [Cites] IEEE Trans Med Imaging. 2006 May;25(5):571-81 [16689261.001]
  • [Cites] Br J Haematol. 2006 Jun;133(6):692-4 [16704450.001]
  • [Cites] Brain. 2006 Nov;129(Pt 11):3042-50 [17071923.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19472-7 [17159154.001]
  • [Cites] N Engl J Med. 2006 Dec 21;355(25):2631-9 [17182988.001]
  • [Cites] Proteomics. 2007 Jan;7(2):299-312 [17205601.001]
  • (PMID = 19476629.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 84955; United States / NCI NIH HHS / CA / R01 CA-112437-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2696469
  •  go-up   go-down


69. Eyenga VC, Ngah JE, Atangana R, Etom E, Ngowe MN, Bassong Y, Oyono JL, Sosso M: [Central nervous system tumours in Cameroon: histopathology and demography]. Sante; 2008 Jan-Mar;18(1):39-42
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Les tumeurs du système nerveux central au Cameroun: histopathologie, démographie.
  • INCLUSION CRITERIA: All cases undergoing surgery in these units for a histologically-confirmed CNS tumour.
  • The average age of patients with metastatic tumors was 42+/-18.5 years compared with 36.5+/-17.8 years for cases with primary tumors.
  • Primary tumors were malignant in 34.2% (n=12) of the children and benign in 65.8% (n=23); among adults 22.7% (n=30) were malignant and 77.3% (n=102) benign.
  • In conclusion, CNS tumors occurred mainly before the age of 55 years and had a slight predilection for girls and women.
  • Meningiomas were the most frequent tumors in adults while astrocytomas were more prevalent in children.
  • [MeSH-major] Brain Neoplasms / epidemiology. Meningeal Neoplasms / epidemiology. Meningioma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Astrocytoma / epidemiology. Astrocytoma / pathology. Brain / pathology. Cameroon. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Meninges / pathology. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18684690.001).
  • [ISSN] 1157-5999
  • [Journal-full-title] Santé (Montrouge, France)
  • [ISO-abbreviation] Sante
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


70. Hsu YC, Chern JJ, Cai Y, Liu M, Choi KW: Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature; 2007 Feb 15;445(7129):785-8
FlyBase. FlyBase .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tuberous sclerosis (TSC) is a benign tumour syndrome caused by mutations in either TSC1 or TSC2 tumour suppressor genes.
  • Activation of the TSC pathway is mediated by Rheb (Ras homologue enriched in brain), a Ras superfamily GTPase.
  • Here we show that a conserved protein, translationally controlled tumour protein (TCTP), is an essential new component of the TSC-Rheb pathway.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Drosophila Proteins / metabolism. Drosophila melanogaster / cytology. Drosophila melanogaster / metabolism. Monomeric GTP-Binding Proteins / metabolism. Neuropeptides / metabolism


71. Evans DG, Birch JM, Ramsden RT, Sharif S, Baser ME: Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet; 2006 Apr;43(4):289-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes.
  • In recent years the use of radiation treatment for benign tumours has increased with the advent of stereotactic delivery and, in particular, single high dose gamma knife therapy.
  • This has been particularly true for benign CNS (central nervous system) tumours such as vestibular schwannoma, meningioma, pituitary adenoma, and haemangioblastoma.
  • While short term follow up in patients with isolated tumours suggests this treatment is safe, there are particular concerns regarding its use in childhood and in tumour predisposing syndromes.
  • We have reviewed the use of radiation treatment in these contexts with particular regard to malignant transformation and new tumour induction.
  • This review indicates that much more caution is warranted regarding the use of radiation treatment for benign tumours in childhood and in tumour prone conditions such as the neurofibromatoses.
  • [MeSH-major] Cell Transformation, Neoplastic. Neoplasms / radiotherapy. Neoplasms, Radiation-Induced / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Br J Cancer. 1986 May;53(5):661-71 [3718823.001]
  • [Cites] N Engl J Med. 1987 May 21;316(21):1289-94 [3574400.001]
  • [Cites] Br J Cancer. 1987 Sep;56(3):339-47 [2822073.001]
  • [Cites] Br J Neurosurg. 1991;5(6):643-6 [1772613.001]
  • [Cites] BMJ. 1992 May 23;304(6838):1343-6 [1611331.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):262-70 [8426203.001]
  • [Cites] Radiology. 1993 Jun;187(3):843-6 [8497642.001]
  • [Cites] Arch Intern Med. 1996 Sep 9;156(16):1873-8 [8790083.001]
  • [Cites] Int J Radiat Biol. 1996 Aug;70(2):145-50 [8794843.001]
  • [Cites] J Med Genet. 1996 Feb;33(2):120-7 [8929948.001]
  • [Cites] Br J Cancer. 1998 Jun;77(12):2181-92 [9649131.001]
  • [Cites] Neurosurgery. 1998 Jul;43(1):28-34; discussion 34-5 [9657185.001]
  • [Cites] Minim Invasive Neurosurg. 2003 Aug;46(4):254-6 [14506573.001]
  • [Cites] Int J Cancer. 2003 Dec 10;107(5):791-6 [14566829.001]
  • [Cites] J Med Genet. 2003 Nov;40(11):802-6 [14627667.001]
  • [Cites] Can J Neurol Sci. 2003 Nov;30(4):378-83 [14672272.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):109-10 [14693854.001]
  • [Cites] Ophthalmology. 2004 Jan;111(1):150-3 [14711727.001]
  • [Cites] Lancet. 2004 Jan 31;363(9406):345-51 [15070562.001]
  • [Cites] Stereotact Funct Neurosurg. 1998 Oct;70 Suppl 1:65-73 [9782237.001]
  • [Cites] Stereotact Funct Neurosurg. 1998 Oct;70 Suppl 1:179-86 [9782249.001]
  • [Cites] Ann Neurol. 1999 Mar;45(3):393-6 [10072056.001]
  • [Cites] J Med Genet. 1999 Mar;36(3):197-203 [10204844.001]
  • [Cites] Br J Cancer. 1999 Apr;79(11-12):1884-93 [10206309.001]
  • [Cites] J Neurosurg. 1999 May;90(5):815-22 [10223445.001]
  • [Cites] Arch Dis Child. 1999 Jan;80(1):1-3 [10325750.001]
  • [Cites] Am J Hum Genet. 1999 Sep;65(3):784-94 [10441587.001]
  • [Cites] Cancer. 1963 Aug;16:1003-14 [14050004.001]
  • [Cites] J Neurosurg. 2005 Jan;102 Suppl:195-9 [15662809.001]
  • [Cites] Br J Neurosurg. 2004 Aug;18(4):338-42 [15702831.001]
  • [Cites] Br J Neurosurg. 2005 Feb;19(1):5-12 [16147576.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2570-5 [16735710.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] J Pediatr. 1989 May;114(5):788-92 [2497236.001]
  • [Cites] Surgery. 1991 Oct;110(4):691-5 [1833847.001]
  • [Cites] Br J Cancer. 1991 Nov;64(5):959-61 [1931625.001]
  • [Cites] Br J Cancer. 2000 Feb;82(4):998 [10732777.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 May;122(5):667-72 [10793343.001]
  • [Cites] Am J Otol. 2000 May;21(3):364-70 [10821550.001]
  • [Cites] Surg Neurol. 2000 Apr;53(4):383-89; discussion 389-90 [10825525.001]
  • [Cites] Br J Neurosurg. 2000 Apr;14(2):93-5 [10889878.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(6):641-4; discussion 644-5 [10949438.001]
  • [Cites] Cancer Invest. 1999;17(1):56-72 [10999050.001]
  • [Cites] Am J Hum Genet. 1999 Oct;65(4):995-1006 [10486318.001]
  • [Cites] Int J Cancer. 2000 Nov 15;88(4):672-8 [11058888.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1381-7 [11121637.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2000;12(5):300-4 [11315715.001]
  • [Cites] Int J Cancer. 2001 Aug 20;96(4):238-42 [11474498.001]
  • [Cites] Oncogene. 2001 Aug 2;20(34):4621-8 [11498785.001]
  • [Cites] J Neurosurg. 2001 Sep;95(3):518-21 [11565878.001]
  • [Cites] Radiat Res. 2002 Feb;157(2):158-65 [11835679.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Nov;55(5):613-6 [11894972.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] J Med Genet. 2002 May;39(5):315-22 [12011146.001]
  • [Cites] Arch Dis Child. 2002 Jul;87(1):65-70 [12089128.001]
  • [Cites] Lancet. 2002 Jul 27;360(9329):309-10 [12147377.001]
  • [Cites] Br J Neurosurg. 2002 Jun;16(3):284-9 [12201399.001]
  • [Cites] Brain. 2003 Jan;126(Pt 1):152-60 [12477702.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1084-92 [12569610.001]
  • [Cites] Eur J Cancer. 2003 Apr;39(6):808-17 [12651207.001]
  • [Cites] Lancet. 2003 Mar 29;361(9363):1101-2 [12672316.001]
  • [Cites] Health Phys. 2003 Jul;85(1):47-59 [12852471.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):618-24 [12879481.001]
  • [Cites] Tumori. 2003 Jul-Aug;89(4 Suppl):197-9 [12903592.001]
  • [Cites] Mayo Clin Proc. 2003 Jun;78(6):708-15 [12934780.001]
  • [Cites] Oncogene. 2003 Sep 1;22(37):5774-83 [12947385.001]
  • [Cites] Cancer. 2004 May 15;100(10):2246-52 [15139071.001]
  • [Cites] Neurochirurgie. 2004 Jun;50(2-3 Pt 2):367-76 [15179291.001]
  • [Cites] JAMA. 1967 Jan 23;199(4):280-1 [4224873.001]
  • [Cites] Am J Surg. 1968 Oct;116(4):518-23 [4300240.001]
  • [Cites] Br J Ophthalmol. 1969 Dec;53(12):793-8 [5386369.001]
  • [Cites] Ann Intern Med. 1977 Aug;87(2):160-4 [889197.001]
  • [Cites] J Natl Cancer Inst. 1979 Jun;62(6):1347-59 [286106.001]
  • [Cites] Arch Dermatol. 1980 Oct;116(10):1159-63 [7425663.001]
  • [Cites] Arch Pathol Lab Med. 1983 Jun;107(6):293-7 [6687792.001]
  • (PMID = 16155191.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 80
  • [Other-IDs] NLM/ PMC2563223
  •  go-up   go-down


72. Wu C, Yen YS, Ho DM, Guo W: Primary neurocytoma in the spinal cord. A case report. Neuroradiol J; 2006 Nov 30;19(5):672-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Central neurocytoma is defined as an intraventricular benign brain tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24351271.001).
  • [ISSN] 1971-4009
  • [Journal-full-title] The neuroradiology journal
  • [ISO-abbreviation] Neuroradiol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Havu-Aurén K, Kiiski J, Lehtiö K, Eskola O, Kulvik M, Vuorinen V, Oikonen V, Vähätalo J, Jääskeläinen J, Minn H: Uptake of 4-borono-2-[18F]fluoro-L-phenylalanine in sporadic and neurofibromatosis 2-related schwannoma and meningioma studied with PET. Eur J Nucl Med Mol Imaging; 2007 Jan;34(1):87-94
Hazardous Substances Data Bank. (L)-Phenylalanine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Boron neutron capture therapy (BNCT) is a chemically targeted form of radiotherapy requiring increased concentration of boron-10 in tumour tissue.
  • Tracer input function and cerebral blood volume were measured.
  • [(18)F]FBPA uptake in tumour and brain was assessed with a three-compartmental model and graphical analysis.
  • These, together with standardised uptake values (SUVs), were used to define tumour-to-brain [(18)F]FBPA tissue activity gradients.
  • Maximum SUV was two- to fourfold higher in tumour as compared with normal brain and independent of NF2 status.
  • The increased uptake was due to higher transport of [(18)F]FBPA in tumour.
  • In multiple-time graphical analysis (MTGA, Gjedde-Patlak plot) the tumour-to-brain [(18)F]FBPA influx constant (K (i) -MTGA) ratios varied between 1.8 and 5.4 in NF2-associated tumours while in sporadic tumours the ratio was 1-1.4.
  • Based on our results on tumour uptake of [(18)F]FBPA, some of these benign neoplasms may be amenable to BNCT.
  • [MeSH-major] Boron Compounds / pharmacokinetics. Brain Neoplasms / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Neurilemmoma / metabolism. Neurofibromatoses / metabolism. Phenylalanine / analogs & derivatives

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Neurofibromatosis.
  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16896669.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Boron Compounds; 0 / Radiopharmaceuticals; 133921-60-5 / 4-borono-2-fluorophenylalanine; 47E5O17Y3R / Phenylalanine
  •  go-up   go-down


74. Hu H, Yao HT, Zhang WP, Zhang L, Ding W, Zhang SH, Chen Z, Wei EQ: Increased expression of aquaporin-4 in human traumatic brain injury and brain tumors. J Zhejiang Univ Sci B; 2005 Jan;6(1):33-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of aquaporin-4 in human traumatic brain injury and brain tumors.
  • OBJECTIVE: To characterize the expression of aquaporin-4 (AQP4), one of the aquaporins (AQPs), in human brain specimens from patients with traumatic brain injury or brain tumors.
  • METHODS: Nineteen human brain specimens were obtained from the patients with traumatic brain injury, brain tumors, benign meningioma or early stage hemorrhagic stroke.
  • MRI or CT imaging was used to assess brain edema.
  • CONCLUSION: AQP4 expression increases in human brains after traumatic brain injury, within brain-derived tumors, and around brain tumors.
  • [MeSH-major] Aquaporins / metabolism. Brain Edema / metabolism. Brain Edema / pathology. Brain Injuries / metabolism. Brain Injuries / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2000 Feb;6(2):159-63 [10655103.001]
  • [Cites] Brain Res Mol Brain Res. 2000 May 31;78(1-2):131-7 [10891592.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):262-5 [11796780.001]
  • [Cites] Brain Res Brain Res Rev. 2002 Jun;39(1):55-73 [12086708.001]
  • [Cites] J Anat. 2002 Jun;200(6):617-27 [12162729.001]
  • [Cites] J Neurosurg. 2003 Mar;98(3):565-9 [12650429.001]
  • [Cites] Acta Neuropathol. 2003 Aug;106(2):121-4 [12715185.001]
  • [Cites] J Biol Chem. 1988 Oct 25;263(30):15634-42 [3049610.001]
  • [Cites] J Neurosci. 1997 Jan 1;17(1):171-80 [8987746.001]
  • [Cites] J Biol Chem. 1997 Jun 27;272(26):16140-6 [9195910.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11981-6 [9751776.001]
  • (PMID = 15593389.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / AQP4 protein, human; 0 / Aquaporin 4; 0 / Aquaporins; 0 / Biomarkers
  • [Other-IDs] NLM/ PMC1390756
  •  go-up   go-down


75. Soria C, Callu D, Viguier D, El Sabbagh S, Bulteau C, Laroussinie F, Dellatolas G: Parental report of cognitive difficulties, quality of life and rehabilitation in children with epilepsy or treated for brain tumour. Dev Neurorehabil; 2008 Oct;11(4):268-75
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parental report of cognitive difficulties, quality of life and rehabilitation in children with epilepsy or treated for brain tumour.
  • In this study, we compare parental report of difficulties and rehabilitation in children with various epileptic syndromes or treated for a benign or malignant brain tumour.
  • METHOD: One hundred fifty-three children aged between 6 and 12 years were included, 119 with epilepsy (non-idiopathic generalized 31, non-idiopathic partial 62, idiopathic 26) and 34 treated for a brain tumour.
  • Report of tiredness was more frequent and of disrupting behaviour less frequent in the tumour group than in epilepsy.
  • [MeSH-major] Brain Neoplasms / rehabilitation. Cognition Disorders. Epilepsy / rehabilitation. Parents. Quality of Life

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19031199.001).
  • [ISSN] 1751-8431
  • [Journal-full-title] Developmental neurorehabilitation
  • [ISO-abbreviation] Dev Neurorehabil
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


76. Sahu S, Lata I, Gupta D: Management of pregnant female with meningioma for craniotomy. J Neurosci Rural Pract; 2010 Jan;1(1):35-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intracranial meningioma during pregnancy challenges the skill of obstetricians, neurosurgeons and neuroanesthesiologists in resection of the tumor and to secure delivery of the baby.
  • Urgent neurosurgical intervention is reserved for the management of malignancies, active hydrocephalus, and benign brain tumors associated with signs of impending herniation or progressive neurological deficit.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Obstet Gynecol Scand. 2001 Feb;80(2):104-12 [11167203.001]
  • [Cites] Am J Obstet Gynecol. 2002 Sep;187(3):626-34 [12237639.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2004 Jun;286(6):H2127-32 [14751854.001]
  • [Cites] Arch Neurol. 1987 Feb;44(2):209-15 [3545159.001]
  • [Cites] J Neurosurg. 1991 Nov;75(5):731-9 [1919695.001]
  • [Cites] Am J Obstet Gynecol. 1994 Oct;171(4):1128-32 [7943085.001]
  • [Cites] J Reprod Med. 1995 Feb;40(2):154-6 [7738930.001]
  • [Cites] Can J Anaesth. 1999 Jan;46(1):61-5 [10078406.001]
  • [Cites] Clin Pharmacokinet. 2005;44(10):989-1008 [16176115.001]
  • [Cites] Pediatrics. 2006 May;117(5):1503-10 [16651303.001]
  • [Cites] Curr Opin Anaesthesiol. 2006 Oct;19(5):481-6 [16960478.001]
  • [Cites] Hypertension. 2007 Feb;49(2):334-40 [17200432.001]
  • [Cites] Anesth Analg. 2008 Jul;107(1):193-200 [18635488.001]
  • [Cites] J Neurosurg. 2009 Dec;111(6):1150-7 [19408979.001]
  • (PMID = 21799618.001).
  • [ISSN] 0976-3155
  • [Journal-full-title] Journal of neurosciences in rural practice
  • [ISO-abbreviation] J Neurosci Rural Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3137832
  • [Keywords] NOTNLM ; Craniotomy / complications / meningioma / pregnancy
  •  go-up   go-down


77. Badr El-Din NK, Settin A, Ali N, Abdel-Hady el-SK, Salem FK: Cytokine gene polymorphisms in egyptian cases with brain tumors. J Egypt Natl Canc Inst; 2009 Jun;21(2):101-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine gene polymorphisms in egyptian cases with brain tumors.
  • BACKGROUND: Cytokines are proposed to play important roles in brain tumor biology as well as neurodegeneration or impaired neuronal function.
  • OBJECTIVES: This work aimed to check the association of polymorphisms of cytokine genes in Egyptian cases with brain tumors.
  • METHODS: This work included 45 cases affected by brain tumors diagnosed as 24 benign and 21 malignant.
  • RESULTS: Cases affected with benign brain tumors showed a significant higher frequency of IL-10-1082 A/A [odds ratio (OR=8.0), p<0.001] and IL-6-174 C/C (OR=6.3, p=0.002) homozygous genotypes as compared to controls.
  • CONCLUSIONS: Cytokine gene polymorphisms showed a pattern of association with brain tumors which may have potential impact on family counseling and disease management.
  • [MeSH-major] Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Cytokines / genetics. Polymorphism, Genetic / genetics
  • [MeSH-minor] Case-Control Studies. DNA / genetics. Egypt. Female. Genotype. Humans. Interleukin 1 Receptor Antagonist Protein / genetics. Interleukin-10 / genetics. Interleukin-6 / genetics. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Tumor Necrosis Factor-alpha / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21057561.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / Interleukin 1 Receptor Antagonist Protein; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 9007-49-2 / DNA
  •  go-up   go-down


78. Andrychowski J, Taraszewska A, Czernicki Z, Jurkiewicz J, Netczuk T, Dabrowski P: Ten years observation and treatment of multifocal pilocytic astrocytoma. Folia Neuropathol; 2009;47(4):362-70
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is a benign, generally well-delineated, WHO grade I tumour with favorable prognosis, which makes it different from diffuse astrocytomas, classified as higher grades of malignancy.
  • A case study of PA was presented in a young female patient, observed and treated at the Neurosurgical Department for the period of 10 years, during which time she had frequent surgical procedures due to recurrence and dissemination of the tumour.
  • Neuroradiological study revealed cerebral tumour in the right temporal lobe, then the first temporal lobe surgery followed by re-operation and radiotherapy was performed.
  • After 5 years local recurrence of the tumour appeared in the right temporal region.
  • The patient was operated and the tumour was totally removed.
  • Initially, the histopathological diagnosis of ganglioglioma was suggested for primary tumour, finally the diagnosis of pilocytic astrocytoma for both recurrent and primary tumour was established.
  • The spinal tumour was surgically treated in both locations; the last operation was done 10 years after surgery of the primary temporal lobe tumour.
  • Histopathological examinations of the excised foci from spinal canal revealed neoplasm consistent with WHO grade I pilocytic astrocytoma.
  • The presented case indicates that despite the spread of the neoplastic process, a histopathologically benign tumour (WHO I grade) allows for long-term survival and observation period.
  • Unfortunately, multifocal tumour involving midline structures causes major neurological symptoms and deficits.

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • Genetic Alliance. consumer health - TEN.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20054789.001).
  • [ISSN] 1509-572X
  • [Journal-full-title] Folia neuropathologica
  • [ISO-abbreviation] Folia Neuropathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


79. Chen G, Liu XY, Wang Z, Liu FY: Vascular endothelial growth factor C: the predicator of early recurrence in patients with N2 non-small-cell lung cancer. Eur J Cardiothorac Surg; 2010 Mar;37(3):546-51
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Cancer tissue samples from 92 patients with pN2 non-small-cell lung cancer and benign lung disease tissues samples from 30 patients were examined by reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry assays to detect VEGF-C expression.
  • All patients with N2 disease were evaluated within 1 year after surgery to detect early tumour recurrence.
  • RESULTS: VEGF-C mRNA expression was observed in 64 (70%) pN2 lung cancer tissues, but was not found in benign lung disease tissues.
  • The main pattern was distant recurrence, and the most frequent sites were the brain and lung.
  • About one-half of the patients with N2 non-small-cell lung cancer would develop recurrence disease within 1 year after surgery, frequently with mediastinal nodes, brain or lung metastases.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Vascular Endothelial Growth Factor C / biosynthesis
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / secondary. Chemotherapy, Adjuvant. Epidemiologic Methods. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Radiotherapy, Adjuvant. Reverse Transcriptase Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • (PMID = 19758816.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / VEGFC protein, human; 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


80. Orakcioglu B, Halatsch ME, Fortunati M, Unterberg A, Yonekawa Y: Intracranial dermoid cysts: variations of radiological and clinical features. Acta Neurochir (Wien); 2008 Dec;150(12):1227-34; discussion 1234
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dermoids are generally benign lesions, but may cause spontaneous complications such as meningitis and/or hydrocephalus due to rupture and epileptic seizures depending on their location.
  • Imaging modalities have changed and can facilitate differential diagnosis and follow-up if applied correctly.
  • RESULTS: Tumour location, size and radiographic characteristics varied in each patient.
  • Diffusion-weighted imaging (DWI) hyperintensity in dermoids is related to decrease of water proton diffusion and should be used for both the diagnosis and follow-up of this lesion.
  • CONCLUSION: Although dermoid cysts are known to be benign entities per se, their rupture can cause a wide range of symptoms including aseptic meningitis and/or hydrocephalus.
  • While rupture does not necessarily bring about hydrocephalus, radical removal of the tumour and close monitoring of ventricular size is required.
  • Although not widely recognised as such, DWI is considered to be a useful imaging modality in the diagnosis and follow-up of dermoids.
  • [MeSH-major] Brain / pathology. Brain / radiography. Brain Neoplasms / diagnosis. Central Nervous System Cysts / diagnosis. Dermoid Cyst / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19020796.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


81. Debling D, Spix C, Blettner M, Michaelis J, Kaatsch P: The cohort of long-term survivors at the German childhood cancer registry. Klin Padiatr; 2008 Nov-Dec;220(6):371-7
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Since 1980 the GCCR systematically ascertains all malignant neoplasms and benign brain tumours in children under the age of 15 years at diagnosis.
  • Participants are followed up actively by the treating hospitals and the clinical study groups in the first years after diagnosis, and by the GCCR thereafter.
  • Those groups are the GCCR (secondary malignant neoplasms), LESS (late effects after chemotherapy), RiSK (late effects after radiotherapy), and the working group on quality of life (quality of life and data on life circumstances).
  • LTS for patients with leukemia and lymphomas is particularly complete, whereas for patients with brain tumours it is less complete.
  • [MeSH-major] Brain Neoplasms / therapy. Leukemia / therapy. Lymphoma / therapy. Neoplasms / therapy. Registries. Survivors
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cohort Studies. Follow-Up Studies. Humans. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / therapy. Young Adult


82. Liu AK, Bagrosky B, Fenton LZ, Gaspar LE, Handler MH, McNatt SA, Foreman NK: Vascular abnormalities in pediatric craniopharyngioma patients treated with radiation therapy. Pediatr Blood Cancer; 2009 Feb;52(2):227-30
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Craniopharyngioma is a benign brain tumor that can be treated with some combination of surgery, intracystic chemotherapy and radiation therapy.
  • One had bilateral temporal cavernomas, one had moyamoya syndrome, one had an aneurysm of the internal carotid artery and three children had decreases in the caliber of the carotid or cerebral arteries, but were asymptomatic.

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Vascular Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18937328.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin
  •  go-up   go-down


83. Pamir MN, Kilic T, Ozek MM, Ozduman K, Türe U: Non-meningeal tumours of the cavernous sinus: a surgical analysis. J Clin Neurosci; 2006 Jul;13(6):626-35
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A retrospective analysis of 42 cases of benign non-meningeal tumours of the cavernous sinus operated on at Marmara University between April 1992 and April 2003 is presented.
  • Twenty-nine percent of patients developed complications, namely cerebrospinal fluid fistula, haematoma, hydrocephalus, diabetes insipidus, cerebral infarction and cranial nerve palsies.
  • Individual tumour characteristics are presented in the text.
  • [MeSH-major] Brain Neoplasms / surgery. Cavernous Sinus / surgery. Neoplasms, Vascular Tissue / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / methods. Cranial Nerve Neoplasms. Female. Follow-Up Studies. Hemangioma, Cavernous, Central Nervous System. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neurilemmoma / surgery. Pituitary Neoplasms / surgery. Retrospective Studies. Tomography, X-Ray Computed / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16860718.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


84. Settin A, Ali N, Salem FK: Cytokine gene polymorphisms in Egyptian cases with brain tumors. Egypt J Immunol; 2008;15(2):15-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine gene polymorphisms in Egyptian cases with brain tumors.
  • Cytokines are proposed to play important roles in brain tumor biology as well as neurodegeneration or impaired neuronal function.
  • To evaluate the association of polymorphisms of cytokine genes with brain tumors in Egyptian patients.
  • This study included 45 cases affected by brain tumors.
  • Their median age was 45, diagnosed as 24 benign cases and 21 malignant cases, and their sex included 20 males and 25 females.
  • Cases affected with benign brain tumors, showed a significant higher frequency of IL-10(-1082) A/A genotype (OR = 8.04, P < 0.001), IL-6(-174) C/C genotype (OR = 6.3, P < 0.001) and TNF-alpha(-308) A/A (OR = 4.7, P < 0.05) with a significant lower frequency of IL-10(-1082) G/A genotype (OR = 0.1, P < 0.001), IL-6(-174) G/C (OR = 0.2, P = 0.001) and TNF-alpha(-308) G/A was found significantly low among the same groups (OR = 0.2, P < 0.001) compared to controls.
  • The frequency of cytokines genotype and allele in malignant brain cases and controls.
  • Comparing studied genotype frequencies among benign and malignant brain tumor cases no significant difference was found in the frequencies of all studied genotypes and alleles with a non significant trend for the benign cases to have higher frequency of IL-10(-1082) AA genotype.
  • In conclusion, cytokine gene polymorphisms have a certain pattern among brain tumor cases and can be considered a genetic marker of potential value in counseling and management.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306684.001).
  • [ISSN] 1110-4902
  • [Journal-full-title] The Egyptian journal of immunology
  • [ISO-abbreviation] Egypt J Immunol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


85. Walter J, Kuhn SA, Brodhun M, Reichart R, Kalff R: Pulmonary meningioma and neurinoma associated with multiple CNS tumours in a patient with neurofibromatosis type 2. Clin Neurol Neurosurg; 2009 Jun;111(5):454-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Neurofibromatosis type 2 (NF2) is a common neurocutaneous disorder that exhibits an autosomal dominant inheritance, with a mutation at chromosome 22q12.2.
  • RESULTS: The reported patient presented a de novo NF2 germline mutation (R341X) and displayed the Wishart-type of NF-2 since she is 11 years old, with a huge anaplastic biparietal falx meningioma and a tentorium meningioma and a tumour-associated parietal mass as well as hypacusis starting at the infant age of 3 years.
  • Moreover, recurrent pulmonary tumours developed and were classified as benign meningiomas and a single neurinoma.
  • No direct evidence concerning a relationship between the pulmonary and cerebral tumours could be drawn.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lung Neoplasms / secondary. Meningioma / secondary. Neurofibromatosis 2 / complications
  • [MeSH-minor] Brain / radiography. Brain Edema. Child. Female. Genes, Neurofibromatosis 2 / physiology. Germ-Line Mutation. Humans. Lung / pathology. Magnetic Resonance Imaging. Tomography, X-Ray Computed


86. Taraszewska A, Matyja E, Koszewski W, Zaczyński A, Bardadin K, Czernicki Z: Asymptomatic and symptomatic glial cysts of the pineal gland. Folia Neuropathol; 2008;46(3):186-95

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glial cysts of the pineal gland are benign and mostly asymptomatic incidental lesions found in the brain MRI or at autopsy examinations.
  • Symptomatic glial cysts may be clinically and radiologically indistinguishable from cystic neoplasms of the pineal region; therefore, histopathological diagnosis is critical for further prognosis and therapy in operated patients.
  • Preoperative MR imaging suggested tumour of the pineal gland in case no. 2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18825594.001).
  • [ISSN] 1641-4640
  • [Journal-full-title] Folia neuropathologica
  • [ISO-abbreviation] Folia Neuropathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


87. Ferchichi L, Bellil S, Ben Hammouda K, Bellil K, Mekni A, Bettaieb I, Haouet S, Khaldi MM, Zitouna K, Kchir N: Anaplastic secretory meningioma: a case report. Pathologica; 2006 Apr;98(2):153-5
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secretory meningiomas are rare histological subtypes of meningiomas with benign biological behaviour.
  • In this study, the authors describe the first case of secretory meningioma with many mitotic figures and brain invasion, and discuss the clinicopathologic features including immunohistochemical staining profile and ultrastructural appearance of this tumour.
  • A case of a 54-year-old man diagnosed with an intracranial tumour located in the left frontal lobe is presented.
  • On pre-contrast CT scans, the tumour was hypodense and the contrast enhancement was marked in the pseudo membrane.
  • The tumour was partially removed.
  • The histological diagnosis was secretory meningioma with many mitotic figures, a high MIB-1 labeling index and a brain invasion.
  • [MeSH-major] Frontal Lobe / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Carcinoembryonic Antigen / analysis. Combined Modality Therapy. Cranial Irradiation. Humans. Keratins / analysis. Ki-67 Antigen / analysis. Male. Middle Aged. Mitotic Index. Mucin-1 / analysis. Neoplasm Invasiveness. Neoplasm Proteins / analysis. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929789.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Ki-67 Antigen; 0 / Mucin-1; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


88. Spoudeas HA, Saran F, Pizer B: A multimodality approach to the treatment of craniopharyngiomas avoiding hypothalamic morbidity: a UK perspective. J Pediatr Endocrinol Metab; 2006 Apr;19 Suppl 1:447-51
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The perception that they are benign tumours cured by radical surgical resection is not borne out by their often difficult excision, propensity to recur and invade, and high late morbidity and mortality from direct brain injury.
  • Evidence suggests that unless the tumour is smaller than 2-4 cm in the mid-line and completely resectable without additional hypothalamic or visual compromise, the surgical approach should be conservative even if this leaves residual tumour.
  • Adjuvant focal radiotherapy to residual or recurrent disease has proven efficacy in long-term tumour control.
  • Thus concerns regarding the potential late toxicity of radiotherapy to the developing brain need to be balanced against the recognised morbidity and mortality of recurrent tumour and repeated neurosurgical interventions.
  • Thus the aims of primary treatment should be to relieve tumour-associated compression symptoms, preserve (or improve) vision and hypothalamo-pituitary function, and minimise tumour recurrence with its attendant high morbidity and mortality.
  • [MeSH-major] Craniopharyngioma / complications. Craniopharyngioma / therapy. Hypothalamic Diseases / etiology. Hypothalamic Diseases / prevention & control. Pituitary Neoplasms / complications. Pituitary Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16700323.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 38
  •  go-up   go-down


89. Blomquist E, Bjelkengren G, Glimelius B: The potential of proton beam radiation therapy in intracranial and ocular tumours. Acta Oncol; 2005;44(8):862-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The estimations have been based on current statistics of tumour incidence, number of patients potentially eligible for radiation treatment, scientific support from clinical trials and model dose planning studies and knowledge of the dose-response relations of different tumours and normal tissues.
  • In intracranial benign and malignant tumours, it is estimated that between 130 and 180 patients each year are candidates for proton beam therapy.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Eye Neoplasms / radiotherapy. Protons / therapeutic use. Radiotherapy Dosage
  • [MeSH-minor] Adenoma / radiotherapy. Chordoma / radiotherapy. Glioma / radiotherapy. Humans. Meningeal Neoplasms / radiotherapy. Pituitary Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted. Skull Neoplasms / radiotherapy. Sweden

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16332593.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Protons
  • [Number-of-references] 93
  •  go-up   go-down


90. Kernick D, Stapley S, Goadsby PJ, Hamilton W: What happens to new-onset headache presented to primary care? A case-cohort study using electronic primary care records. Cephalalgia; 2008 Nov;28(11):1188-95
MedlinePlus Health Information. consumer health - Headache.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Records of patients who presented with primary headache (migraine, tension-type headache, cluster headache) or undifferentiated headache (no further descriptor) were examined for the subsequent year for subarachnoid haemorrhage, primary brain tumour, benign space-occupying lesion, temporal arteritis, stroke and transient ischaemic attack.
  • The 1-year risk of a malignant brain tumour with new undifferentiated headache was 0.15%, rising to 0.28% above the age of 50 years.
  • The risk for a benign space-occupying lesion was 0.05% for an undifferentiated and 0.009% for a primary headache.
  • Accepting the limitations of this approach, our data can inform management guidelines for new presentations of headache in primary care and confirm the need for follow-up, even if a primary headache diagnosis is made.
  • [MeSH-major] Headache / diagnosis. Headache / epidemiology. Headache / etiology
  • [MeSH-minor] Adult. Brain Diseases / complications. Case-Control Studies. Female. Humans. Male. Middle Aged. Primary Health Care

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Headache. 2011 Feb;51(2):346-52 [21284622.001]
  • (PMID = 18771496.001).
  • [ISSN] 1468-2982
  • [Journal-full-title] Cephalalgia : an international journal of headache
  • [ISO-abbreviation] Cephalalgia
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


91. Büchler T, Vorzilková E, Koukolík F, Melínova H, Abrahámová J: [Malignant subtype of cystosarcoma phyllodes with brain metastases]. Klin Onkol; 2010;23(6):446-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant subtype of cystosarcoma phyllodes with brain metastases].
  • [Transliterated title] Maligní forma cystosarcoma phyllodes s metastázami do mozku.
  • Cystosarcoma phyllodes is an uncommon type of breast tumour.
  • Benign, borderline, and malignant subtypes have been described.
  • We report on a patient with malignant cystosarcoma phyllodes who developed metastatic disease six years after resection of the primary breast tumour.
  • Partial regression of a brain metastasis was achieved using radiotherapy but the patient later died due to widespread metastatic disease which was uncontrollable by systemic chemotherapy.
  • Because metastatic malignant cystosarcoma phyllodes are largely resistant to treatment, the most important objective is to provide optimal management of the primary tumour before dissemination occurs.
  • [MeSH-major] Brain Neoplasms / secondary. Breast Neoplasms / pathology. Phyllodes Tumor / secondary

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21351423.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


92. Hardell L, Carlberg M: Mobile phones, cordless phones and the risk for brain tumours. Int J Oncol; 2009 Jul;35(1):5-17
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mobile phones, cordless phones and the risk for brain tumours.
  • The Hardell-group conducted during 1997-2003 two case control studies on brain tumours including assessment of use of mobile phones and cordless phones.
  • The questionnaire was answered by 905 (90%) cases with malignant brain tumours, 1,254 (88%) cases with benign tumours and 2,162 (89%) population-based controls.
  • Anatomical area in the brain for the tumour was assessed and related to side of the head used for both types of wireless phones.
  • In the current analysis we defined ipsilateral use (same side as the tumour) as >or=50% of the use and contralateral use (opposite side) as <50% of the calling time.
  • However, the medical diagnosis and treatment of this tumour type has changed during recent years and underreporting from a single center would have a large impact for such a rare tumour.
  • [MeSH-major] Brain Neoplasms / etiology. Cell Phones. Microwaves / adverse effects. Neoplasms, Radiation-Induced / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19513546.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


93. Huang Z, Zuo C, Guan Y, Zhang Z, Liu P, Xue F, Lin X: Misdiagnoses of 11C-choline combined with 18F-FDG PET imaging in brain tumours. Nucl Med Commun; 2008 Apr;29(4):354-8
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Misdiagnoses of 11C-choline combined with 18F-FDG PET imaging in brain tumours.
  • BACKGROUND AND OBJECTIVE: The widely applied F-FDG is known for its disadvantage in brain tumour PET imaging because of its high background uptake.
  • C-choline can achieve high contrast of brain tumour imaging and was expected to have higher sensitivity and specificity.
  • We analysed the misdiagnoses in C-choline PET imaging in brain tumours with the aim of improving the accuracy of diagnosis with C-choline PET imaging.
  • PATIENTS AND METHODS: We selected 10 patients proven to have been misdiagnosed on the basis of histopathological correlation and clinical follow-up among 94 patients (110 studies) who underwent C-choline PET/CT for diagnosed or suspected brain tumour between 23 March 2005 and 8 February 2007.
  • RESULTS: Of all 10 misdiagnosed patients, five were false positive (one abscess, one tuberculosis, one benign gliocyte proliferation, one inflammatory granuloma and one demyelination), four were false negative (two metastases from lung cancer, one lymphoma, one grade II glioma) and one was misdiagnosed by wrong interpretation due to lack of experience.
  • The rate of false positives was (5/110) 4.55%; the rate of false negatives was (4/110) 3.64%; the accuracy of C-choline alone was (93/110) 84.5%; by comparison, the accuracy of F-FDG alone was (78/110) 70.9%.
  • With proper application, C-choline might have greater potential than F-FDG for brain tumour PET imaging.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Choline. Diagnostic Errors / prevention & control. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317300.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; N91BDP6H0X / Choline
  •  go-up   go-down


94. Chesnokova V, Melmed S: Pituitary tumour-transforming gene (PTTG) and pituitary senescence. Horm Res; 2009 Apr;71 Suppl 2:82-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary tumour-transforming gene (PTTG) and pituitary senescence.
  • Pituitary tumours account for 15% of intracranial neoplasms and are benign monoclonal neoplasms that may be clinically silent or secrete hormones, including prolactin, growth hormone, adrenocorticotrophic hormone or, rarely, thyroid-stimulating hormone or gonadotrophins.
  • We explored the role of disordered pituitary cell proliferation control in the pathogenesis of these invariably benign adenomas, studying the mechanisms underlying pituitary aneuploidy, premature proliferative arrest (senescence), markers of cell proliferation and tumorigenesis in single, double or triply mutant transgenic mice with mutations of Rb, Pttg and/or p21.
  • [MeSH-major] Brain Neoplasms / metabolism. Cell Aging. Cell Cycle. Mutation. Neoplasm Proteins / metabolism. Pituitary Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19407503.001).
  • [ISSN] 1423-0046
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Pituitary Hormones; 0 / Retinoblastoma Protein; 0 / Securin; 0 / pituitary tumor-transforming protein 1, human
  • [Number-of-references] 38
  •  go-up   go-down


95. Pandita A, Balasubramaniam A, Perrin R, Shannon P, Guha A: Malignant and benign ganglioglioma: a pathological and molecular study. Neuro Oncol; 2007 Apr;9(2):124-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant and benign ganglioglioma: a pathological and molecular study.
  • Gangliogliomas are generally benign tumors, composed of transformed neuronal and glial elements, with rare malignant progression of the glial component.
  • Conventional and array comparative genomic hybridization (approximately 2.5-Mb resolution) analyses found chromosomal losses to be predominant in the benign areas of the ganglioglioma, with gains more prevalent in the malignant component.
  • Deciphering the specific genes residing in these chromosomal regions may further our understanding of not only these rare tumors but also the more common gliomas.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Ganglioglioma / genetics. Ganglioglioma / pathology
  • [MeSH-minor] Adult. Chromosome Mapping. DNA, Neoplasm / genetics. DNA, Neoplasm / isolation & purification. Female. Genes, p16. Genes, p53. Humans. Oligonucleotide Array Sequence Analysis. Receptors, Androgen / genetics. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ganglioglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytogenet Genome Res. 2004;107(1-2):77-82 [15305059.001]
  • [Cites] Neoplasia. 1999 Aug;1(3):262-75 [10935481.001]
  • [Cites] Neurosurgery. 1983 Aug;13(2):124-8 [6888690.001]
  • [Cites] Science. 1992 Oct 30;258(5083):818-21 [1359641.001]
  • [Cites] Am J Pathol. 1995 Feb;146(2):501-8 [7856759.001]
  • [Cites] Am J Pathol. 1995 Mar;146(3):613-9 [7887443.001]
  • [Cites] Nucleic Acids Res. 1995 Apr 25;23(8):1411-8 [7753634.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):5080-4 [7585555.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):150-3 [8548755.001]
  • [Cites] J Neuropathol Exp Neurol. 1996 Jul;55(7):822-31 [8965097.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):565-71 [9250169.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Apr;21(4):340-6 [9559346.001]
  • [Cites] Br J Cancer. 1999 Aug;80(12):2034-9 [10471057.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):41-6 [10471496.001]
  • [Cites] Cancer Genet Cytogenet. 2005 May;159(1):69-73 [15860361.001]
  • [Cites] J Neurooncol. 2005 Apr;72(2):103-6 [15925988.001]
  • [Cites] Adv Cancer Res. 2005;94:1-27 [16095998.001]
  • [Cites] Am J Dermatopathol. 2005 Aug;27(4):279-85 [16121045.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6177-85 [16144918.001]
  • [Cites] Lab Invest. 2001 May;81(5):717-23 [11351043.001]
  • [Cites] J Neurosurg. 2001 Jul;95(1):138-42 [11453385.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5895-904 [11479231.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):807-12 [12213708.001]
  • [Cites] Neoplasia. 2003 Jan-Feb;5(1):53-62 [12659670.001]
  • [Cites] Pathol Int. 2003 Dec;53(12):874-82 [14629754.001]
  • [Cites] Int J Oncol. 2006 Mar;28(3):667-74 [16465372.001]
  • [Cites] Breast Cancer Res. 2006;8(1):R9 [16417655.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1571-83 [16247447.001]
  • [Cites] J Neurosurg. 1981 Jan;54(1):58-63 [7463121.001]
  • (PMID = 17259542.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Receptors, Androgen
  • [Other-IDs] NLM/ PMC1871674
  •  go-up   go-down


96. Insausti I, Cabada T, Caballero C, Zazpe I, Bacaicoa MC, Olier J: [Symptomatic xanthogranuloma of the lateral ventricle]. Neurocirugia (Astur); 2009 Jun;20(3):278-81
Genetic Alliance. consumer health - Xanthogranuloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Xantogranuloma sintomático del ventrículo lateral. A propósito de un caso.
  • Xanthogranulomas of the choroid plexus is a benign tumour of uncertain etiology, usually asymptomatic.
  • [MeSH-minor] Brain Edema / pathology. Choroid Plexus / pathology. Humans. Male. Middle Aged. Seizures / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575133.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


97. Khong SY, Leach J, Greenwood C: Meningioma mimicking puerperal psychosis. Obstet Gynecol; 2007 Feb;109(2 Pt2):515-6
MedlinePlus Health Information. consumer health - Psychotic Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Meningiomas are slow-growing benign brain tumors.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Psychotic Disorders / etiology. Puerperal Disorders / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Pregnancy. Pregnancy Trimester, Third

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Postpartum Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17267878.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. De Marinis L, Fusco A, Bianchi A, Aimaretti G, Ambrosio MR, Scaroni C, Cannavo S, Di Somma C, Mantero F, degli Uberti EC, Giordano G, Ghigo E: Hypopituitarism findings in patients with primary brain tumors 1 year after neurosurgical treatment: preliminary report. J Endocrinol Invest; 2006 Jun;29(6):516-22
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypopituitarism findings in patients with primary brain tumors 1 year after neurosurgical treatment: preliminary report.
  • It may occur after neurosurgical treatment of brain tumors arising near sella turcica.
  • The aim of this study was to evaluate pituitary function in particular GH deficiency (GHD) in patients submitted to neurosurgery for benign tumors of the central nervous system (CNS) not involving hypothalamic-pituitary region.
  • We observed 37 patients with benign brain tumors [13 males, 24 females, age: 54.6+/-13.9 yr; body mass index (BMI): 25.1+/-4.0 kg/m2] performing a basic evaluation of the pituitary function and a dynamic test of the GH/IGF-I axis [GHRH (1 microg/kg iv)+arginine (0.5 g/kg iv) test] for 3 and 12 months after the neurosurgical treatment.
  • This data suggests that hypopituitarism of various degree may develop in patients who are submitted to neurosurgery for primary brain tumors, even far from hypothalamic-pituitary region.
  • [MeSH-major] Brain Neoplasms / surgery. Hypopituitarism / etiology. Postoperative Complications

  • Genetic Alliance. consumer health - Hypopituitarism.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840829.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Somatomedins; 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; 9002-71-5 / Thyrotropin; 9002-72-6 / Growth Hormone; 9034-39-3 / Growth Hormone-Releasing Hormone; 94ZLA3W45F / Arginine; Q51BO43MG4 / Thyroxine; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


99. Tanriover N, Kacira T, Ulu MO, Gazioglu N, Oz B, Uzan M: Epidermoid tumour within the collateral sulcus: a rare location and atypical presentation. J Clin Neurosci; 2008 Aug;15(8):950-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermoid tumour within the collateral sulcus: a rare location and atypical presentation.
  • Epidermoid tumours (ETs) are uncommon benign lesions that may grow by spreading in the subarachnoid space of the basal cisterns and expanding to conform to the shape of specific sulci and fissures.
  • MRI of the brain revealed a right temporobasal mass lesion, hypointense on T(1)-weighted and hyperintense on T(2)-weighted images, with minimal contrast enhancement, on the basal surface of the temporal lobe.
  • [MeSH-major] Brain Neoplasms / pathology. Epidermal Cyst / pathology. Temporal Lobe / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18434160.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


100. Sugo N, Yokota K, Kondo K, Harada N, Aoki Y, Miyazaki C, Nemoto M, Kano T, Ohishi H, Seiki Y: Early dynamic 201Tl SPECT in the evaluation of brain tumours. Nucl Med Commun; 2006 Feb;27(2):143-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early dynamic 201Tl SPECT in the evaluation of brain tumours.
  • OBJECTIVE: To estimate the usefulness of early dynamic 201Tl single photon emission computed tomography (SPECT) studies in distinguishing the histological malignancy of brain tumours.
  • METHODS: Dynamic 201Tl SPECT was performed for 3 min per scan for 15 min immediately after the administration of 201TlCl in 110 patients with brain tumours (111 lesions).
  • For static SPECT, the static thallium index (STI) was calculated as the ratio of 201Tl uptake in the tumour to that of the contralateral normal brain.
  • RESULTS: In static SPECT, there was no significant difference between the STI of malignant tumours (glioblastoma and anaplastic astrocytoma) and that of benign tumours (low-grade glioma, meningioma, pituitary adenoma, neurinoma and haemangioblastoma) (3.7+/-1.5, 5.0+/-3.5, respectively).
  • In contrast, the DTI of benign tumours increased slightly, steadily or decreased.
  • The slope of the linear functions calculated from the DTRs was much higher in the malignant tumour group than in the benign tumour group (P<0.001).
  • CONCLUSIONS: We suggest that the performance of 201Tl dynamic SPECT for 15 min is useful for distinguishing malignant brain tumours from benign brain tumours and reduces the examination stress of patients.
  • [MeSH-major] Brain Neoplasms / classification. Brain Neoplasms / radionuclide imaging. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Severity of Illness Index. Thallium. Tomography, Emission-Computed, Single-Photon / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. THALLIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. THALLOUS CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16404227.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 7791-12-0 / thallium chloride; AD84R52XLF / Thallium
  •  go-up   go-down






Advertisement